

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 1 of 77

Factors influencing baseline and change over 6 weeks in  
WEB-based IBS-SSS, IBS-QOL, IBDQ, SCCAI, HBI, FC, CRP and  
FODMAPS score:

Results based on 78 subjects in a controlled clinical trial

Author: Carsten Henrik Wachmann

Principal Statistician

Larix A/S

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 2 of 77

## Table of Contents

Table1: Distribution of IBS-SSS, IBS-QOL, IBDQ, SCCAI and HBI at baseline, week 6 and the difference. ....	3
Table2: Distribution of IBS_QOL DOMAIN scores at baseline and the difference. 108 patients.....	14
Table3: IBS-SSS categories at baseline versus at week 6 .....	15
Table4: SCCAI categories at baseline versus at week 6.....	16
Table5: HBI categories at baseline versus at week 6 .....	17
Figure1: IBS-SSS, IBS-QOL and IBDQ cumulative distributions.....	18
Figure2: Change in IBS-SSS .....	20
Figure3: Change in IBS-QOL .....	22
Figure4: Change in IBDQ.....	24
Figure5: Change in IBS-QOL versus change in IBS-SSS .....	26
Figure6: Change in IBDQ, SCCAI and HBI versus change in IBS-SSS .....	26
Figure7: Number of stools/day: change versus baseline .....	28
Figure8: histograms and box-plots.....	29
Table6: IBS-SSS at baseline: analysis of COVARIANCE: .....	33
Table7: IBS-SSS CHANGE from baseline to week 6: analysis of COVARIANCE: .....	33
Table8: IBS-QOL at baseline: analysis of COVARIANCE .....	34
Table9: IBS-QOL CHANGE from baseline to week 6: analysis of COVARIANCE:.....	34
Table10: IBDQ at baseline: analysis of COVARIANCE .....	35
Table11: Change from baseline in IBDQ: analysis of COVARIANCE .....	35
Table12: IBS-SSS responder analysis .....	36
Table13: Distribution of FC, CRP and FODMAPS at baseline, week 6 and the difference. ....	38
Table 14: FC and CRP categories (0/1) at baseline versus at week 6.....	41
Figure 9: Scatterplots for SCCAI, HBI, FC, CRF and FODMAPS.....	42
Table 15: Detailed tables for endpoints according to Intervention/Control .....	45
Figure 10: Alternative plots for IBS_SSS including regression lines .....	61
Figure 11: Alternative plots for IBS_QOL including regression lines.....	63
Figure 12: Alternative plots for IBDQ including regression lines .....	65
Figure 13: Alternative plots for SCCAI including regression lines .....	67
Figure 14: Alternative plots for HBI including regression lines.....	69
Figure 15: Alternative plots for FC including regression lines.....	71
Figure 16: Alternative plots for FC including regression lines.....	73
Figure 17: Alternative plots for FC including regression lines.....	75
Table16: FODMAPS at baseline: analysis of COVARIANCE.....	77
Table17: Change from baseline in FODMAPS: analysis of COVARIANCE .....	77

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 3 of 77

**Table1: Distribution of IBS-SSS, IBS-QOL, IBDQ, SCCAI and HBI at baseline, week 6 and the difference.**

	Treatment										
	FODMAP										
	SSS1			SSS2			Dif SSS			Responder	
	N	Mean	Std	N	Mean	Std	N	Mean	Std	N	%
All	37	232.3	78.8	37	118.7	104.7	37	-114	96.2	37	0.81
Age 35											
<=35	13	238.5	70.4	13	128.8	115.0	13	-110	97.2	13	0.85
> 35	24	229.0	84.3	24	113.2	100.8	24	-116	97.7	24	0.79
IBD duration											
.	.	.	.	.	.	.	.	.	.	.	.
<=5 y	15	238.8	85.4	15	153.0	111.5	15	-85.8	101.5	15	0.73
> 5 y	22	227.9	75.8	22	95.3	95.3	22	-133	89.8	22	0.86
Gender											
male	12	249.1	87.7	12	115.7	67.3	12	-133	101.1	12	0.83
female	25	224.2	74.7	25	120.1	119.8	25	-104	94.4	25	0.80
Intestinal surgery yes vs. no											
yes	10	238.2	83.4	10	118.8	113.5	10	-119	71.3	10	0.90
no	27	230.1	78.6	27	118.6	103.5	27	-111	105.1	27	0.78
Smoking											
never	15	252.6	85.8	15	137.1	99.4	15	-115	112.3	15	0.80
former smoker	16	198.6	65.7	16	78.3	73.9	16	-120	83.3	16	0.81
currently	6	271.5	66.6	6	180.2	155.0	6	-91.3	99.0	6	0.83
Diagnosis type											
CD	11	227.5	83.0	11	108.4	135.6	11	-119	87.2	11	0.91
UC	26	234.3	78.6	26	123.0	91.4	26	-111	101.3	26	0.77
Therapy five levels at baseline											
.	8	240.3	69.7	8	95.5	152.5	8	-145	104.8	8	0.88
5-ASA+-topical 5asa+-topical_ster	22	218.7	66.4	22	112.9	79.9	22	-106	100.1	22	0.77
immunomodulators (AZA+-MTX)	3	206.0	102.9	3	104.3	107.4	3	-102	23.1	3	1.00
Biologicals with any of aboth combination	4	311.0	121.6	4	207.5	111.6	4	-104	108.0	4	0.75
Disease activity (relapse) baseline yes no											
yes	6	270.3	113.5	6	200.0	122.1	6	-70.3	125.6	6	0.67
no	31	224.9	70.4	31	102.9	95.3	31	-122	89.6	31	0.84

NOTE: Signed rank test for change (from zero) in **FODMAP IBS-SSS: p<0.0001**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 4 of 77

	Treatment										
	control										
	SSS1			SSS2			Dif SSS			Responder	
	N	Mean	Std	N	Mean	Std	N	Mean	Std	N	%
All	41	248.7	99.7	41	180.6	117.8	41	-68.1	95.2	41	0.46
Age 35											
<=35	13	268.5	93.3	13	191.8	124.1	13	-76.6	107.2	13	0.38
> 35	28	239.5	102.9	28	175.4	116.7	28	-64.1	90.9	28	0.50
IBD duration											
.	1	220.0	.	1	189.0	.	1	-31.0	.	1	0.00
<=5 y	17	270.4	91.6	17	229.8	98.8	17	-40.6	94.4	17	0.35
> 5 y	23	233.8	106.5	23	143.8	121.8	23	-90.0	94.0	23	0.57
Gender											
male	7	264.3	105.0	7	136.7	104.0	7	-128	133.8	7	0.57
female	34	245.4	99.9	34	189.6	119.8	34	-55.8	82.6	34	0.44
Intestinal surgery yes vs. no											
yes	2	207.5	53.0	2	196.5	37.5	2	-11.0	15.6	2	0.00
no	39	250.8	101.5	39	179.8	120.6	39	-71.0	96.7	39	0.49
Smoking											
never	29	254.5	102.9	29	182.8	115.5	29	-71.7	99.6	29	0.48
former smoker	11	229.5	97.4	11	174.7	134.5	11	-54.8	89.5	11	0.36
currently	1	290.0	.	1	180.0	.	1	-110	.	1	1.00
Diagnosis type											
CD	12	262.2	112.3	12	238.8	106.2	12	-23.3	63.9	12	0.25
UC	29	243.1	95.6	29	156.5	115.5	29	-86.6	100.6	29	0.55
Therapy five levels at baseline											
.	6	206.7	99.1	6	172.2	121.1	6	-34.5	38.6	6	0.17
5-ASA+-topical 5asa+-topical_ster	25	257.6	91.7	25	159.8	120.7	25	-97.8	102.1	25	0.60
immunomodulators (AZA+-MTX)	7	242.3	125.9	7	233.7	106.9	7	-8.6	69.9	7	0.29
Biologicals with any of aboth combination	3	273.3	135.8	3	246.7	98.7	3	-26.7	90.7	3	0.33
Disease activity (relapse) baseline yes no											
yes	7	261.4	92.5	7	151.3	92.8	7	-110	115.7	7	0.71
no	34	246.0	102.3	34	186.6	122.6	34	-59.4	89.9	34	0.41

NOTE: Signed rank test for change (from zero) in

**CONTROL IBS-SSS: p<0.0001**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 5 of 77

	SSS1			SSS2			Dif SSS			Responder	
	N	Mean	Std	N	Mean	Std	N	Mean	Std	N	%
<b>All subjects</b>	78	240.9	90.2	78	151.2	115.3	78	<b>-89.7</b>	97.8	78	0.63
Age 35											
<=35	26	253.5	82.4	26	160.3	121.6	26	-93.1	101.6	26	0.62
> 35	52	234.6	94.0	52	146.7	113.0	52	-88.0	96.7	52	0.63
IBD duration											
.	1	220.0	.	1	189.0	.	1	-31.0	.	1	0.00
<=5 y	32	255.6	88.8	32	193.8	110.3	32	-61.8	98.9	32	0.53
> 5 y	45	230.9	91.8	45	120.1	111.2	45	-111	93.4	45	0.71
Gender											
male	19	254.7	91.8	19	123.4	80.5	19	-131	110.6	19	0.74
female	59	236.5	90.0	59	160.2	123.7	59	-76.3	90.2	59	0.59
Intestinal surgery yes vs. no											
yes	12	233.1	78.0	12	131.8	107.6	12	-101	77.2	12	0.75
no	66	242.3	92.7	66	154.8	117.1	66	-87.6	101.4	66	0.61
Smoking											
never	44	253.8	96.4	44	167.3	111.3	44	-86.6	104.9	44	0.59
former smoker	27	211.2	79.9	27	117.6	111.6	27	-93.6	90.3	27	0.63
currently	7	274.1	61.2	7	180.1	141.5	7	-94.0	90.6	7	0.86
Diagnosis type											
CD	23	245.6	98.8	23	176.4	135.8	23	-69.1	88.8	23	0.57
UC	55	238.9	87.3	55	140.7	105.2	55	-98.3	100.8	55	0.65
Treatment group FODMAP Kontrol											
intervention	37	<b>232.3</b>	78.8	37	118.7	104.7	37	<b>-114</b>	96.2	37	0.81
control	41	<b>248.7</b>	99.7	41	180.6	117.8	41	<b>-68.1</b>	95.2	41	0.46
Therapy five levels at baseline											
.	14	225.9	81.8	14	128.4	140.4	14	-97.5	98.5	14	0.57
5-ASA+-topical 5asa+-topical_ster	47	239.4	82.4	47	137.9	105.2	47	-102	100.1	47	0.68
immunomodulators (AZA+-MTX)	10	231.4	115.0	10	194.9	118.7	10	-36.5	73.5	10	0.50
Biologicals with any of aboth combination	7	294.9	118.1	7	224.3	99.6	7	-70.6	101.3	7	0.57
Disease activity (relapse) baseline yes no											
yes	13	265.5	98.3	13	173.8	105.6	13	-91.8	117.1	13	0.69
no	65	236.0	88.5	65	146.7	117.4	65	-89.3	94.5	65	0.62

NOTE: IBS-SSS results on 0-500 scale (0-75 remission, 75-175 mild, 175-300 moderate, 300-500 severe)

IBS-SSS responder: SSS2 - SSS1 <= -50

NOTE: Signed rank test for change (from zero) in IBS-SSS: **p<0.0001**

NOTE: Wilcoxon rank test for TREATMENT influence on  $\Delta$ IBS-SSS: **p=0.017**

NOTE: Wilcoxon rank test for TREATMENT allocation on IBS-SSS1: **p=0.40**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 6 of 77

	Responder		Q1 Resp.		Q2 Resp.		Q3 Resp.		Q4 Resp.		Q5 Resp.	
	N	%	N	%	N	%	N	%	N	%	N	%
All	78	0.63	78	0.44	78	0.55	78	0.73	78	0.50	78	0.64
Age 35												
<=35	26	0.62	26	0.54	26	0.77	26	0.65	26	0.54	26	0.69
> 35	52	0.63	52	0.38	52	0.44	52	0.77	52	0.48	52	0.62
IBD duration												
.	1	0.00	1	0.00	1	0.00	1	1.00	1	0.00	1	1.00
<=5 y	32	0.53	32	0.28	32	0.53	32	0.63	32	0.47	32	0.50
> 5 y	45	0.71	45	0.56	45	0.58	45	0.80	45	0.53	45	0.73
Gender												
male	19	0.74	19	0.47	19	0.74	19	0.74	19	0.68	19	0.63
female	59	0.59	59	0.42	59	0.49	59	0.73	59	0.44	59	0.64
Intestinal surgery yes vs. no												
yes	12	0.75	12	0.50	12	0.67	12	0.75	12	0.58	12	0.58
no	66	0.61	66	0.42	66	0.53	66	0.73	66	0.48	66	0.65
Smoking												
never	44	0.59	44	0.45	44	0.55	44	0.75	44	0.41	44	0.64
former smoker	27	0.63	27	0.44	27	0.48	27	0.70	27	0.59	27	0.63
currently	7	0.86	7	0.29	7	0.86	7	0.71	7	0.71	7	0.71
Diagnosis type												
CD	23	0.57	23	0.35	23	0.65	23	0.61	23	0.39	23	0.61
UC	55	0.65	55	0.47	55	0.51	55	0.78	55	0.55	55	0.65
Treatment group												
<b>FODMAP</b>	<b>37</b>	<b>0.81</b>	<b>37</b>	<b>0.49</b>	<b>37</b>	<b>0.68</b>	<b>37</b>	<b>0.76</b>	<b>37</b>	<b>0.62</b>	<b>37</b>	<b>0.68</b>
<b>Control</b>	<b>41</b>	<b>0.46</b>	<b>41</b>	<b>0.39</b>	<b>41</b>	<b>0.44</b>	<b>41</b>	<b>0.71</b>	<b>41</b>	<b>0.39</b>	<b>41</b>	<b>0.61</b>
Therapy five levels at baseline												
.	14	0.57	14	0.43	14	0.64	14	0.64	14	0.57	14	0.71
5-ASA+-topical 5asa+-topical_ster	47	0.68	47	0.49	47	0.51	47	0.81	47	0.51	47	0.68
immunomodulators (AZA+-MTX)	10	0.50	10	0.20	10	0.50	10	0.70	10	0.30	10	0.60
Biologicals with any of aboth combination	7	0.57	7	0.43	7	0.71	7	0.43	7	0.57	7	0.29
Disease activity (relapse) baseline yes no												
yes	13	0.69	13	0.31	13	0.54	13	0.69	13	0.62	13	0.62
no	65	0.62	65	0.46	65	0.55	65	0.74	65	0.48	65	0.65

NOTE: an (IBS-SSS) RESPONDER defined as a subject having at least 50 IBS-SSS points drop (maximum from 500 down to 0) during study. 'Q1 responder' defined as at least 10 points drop in Q1-component of IBS-SSS.

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 7 of 77

	QOL1			QOL2			Dif QOL		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
All	77	69.3	19.8	77	72.7	21.6	77	3.4	11.4
Age 35									
<=35	25	63.6	19.1	25	69.0	23.8	25	5.3	10.2
> 35	52	72.1	19.7	52	74.5	20.5	52	2.5	11.9
IBD duration									
.	1	88.2	.	1	74.3	.	1	-14.0	.
<=5 y	31	67.8	20.3	31	68.6	22.1	31	0.8	10.6
> 5 y	45	69.9	19.6	45	75.5	21.3	45	5.6	11.4
Gender									
male	18	75.3	22.2	18	79.6	21.7	18	4.3	10.2
female	59	67.5	18.8	59	70.6	21.3	59	3.1	11.7
Intestinal surgery yes vs. no									
yes	12	64.8	21.1	12	70.5	24.0	12	5.7	11.1
no	65	70.2	19.6	65	73.1	21.3	65	3.0	11.5
Smoking									
never	43	68.0	19.8	43	71.2	22.1	43	3.2	10.1
former smoker	27	73.7	18.5	27	78.1	17.6	27	4.4	13.9
currently	7	60.6	23.2	7	61.6	29.2	7	0.9	8.0
Diagnosis type									
CD	23	65.7	21.3	23	69.7	24.5	23	3.9	10.5
UC	54	70.9	19.1	54	74.0	20.3	54	3.2	11.8
Treatment group FODMAP Kontrol									
intervention	36	67.2	19.5	36	73.5	21.1	36	6.4	11.2
control	41	71.2	20.0	41	72.0	22.3	41	0.8	11.0
Therapy five levels at baseline									
.	14	69.2	19.0	14	76.2	20.6	14	7.0	12.5
5-ASA+-topical 5asa	46	72.7	17.7	46	76.9	18.1	46	4.2	11.8
immunomodulators (AZA+-MTX)	10	68.8	24.2	10	66.4	28.2	10	-2.4	8.9
Biologics	7	48.0	18.1	7	47.2	19.1	7	-0.8	3.5
Disease activity (relapse) baseline yes no									
yes	13	59.0	20.0	13	61.5	23.1	13	2.4	9.3
no	64	71.4	19.2	64	75.0	20.7	64	3.6	11.8

NOTE: All IBS-QOL results on 0-100 scale (0 worst, 100 best)

NOTE: Signed rank test for change (from zero) in IBS-QOL: **p=0.003** (FODMAP: p=0.001, Control: p=0.301)

NOTE: Wilcoxon rank test for TREATMENT influence on  $\Delta$ IBS-QOL: **p=0.091**

NOTE: Wilcoxon rank test for TREATMENT allocation on IBS-QOL1: **p=0.259**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 8 of 77

	IBDQ1			IBDQ2			Dif IBDQ		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
All	74	47.8	10.2	72	52.8	12.6	71	4.7	10.6
Age 35									
<=35	25	44.6	10.5	24	49.7	13.4	23	4.6	11.4
> 35	49	49.4	9.7	48	54.4	12.0	48	4.8	10.3
IBD duration									
.	1	59.0	.	1	59.0	.	1	0.0	.
<=5 y	30	47.0	9.2	27	48.9	10.5	27	1.5	8.4
> 5 y	43	48.0	10.9	44	55.1	13.5	43	6.8	11.5
Gender									
male	16	49.2	11.0	16	55.6	10.7	15	5.4	9.5
female	58	47.4	10.0	56	52.1	13.1	56	4.5	10.9
Intestinal surgery yes vs. no									
yes	11	45.9	8.5	12	54.5	10.3	11	7.5	8.3
no	63	48.1	10.5	60	52.5	13.1	60	4.2	10.9
Smoking									
never	41	47.4	9.7	40	51.1	13.5	39	3.3	11.3
former smoker	27	49.0	11.7	26	56.0	10.9	26	6.4	9.9
currently	6	44.8	6.4	6	51.2	12.6	6	6.3	8.6
Diagnosis type									
CD	21	45.5	8.7	22	49.5	12.8	21	3.2	8.3
UC	53	48.7	10.7	50	54.3	12.4	50	5.3	11.4
Treatment group FODMAP Kontrol									
intervention	34	47.8	9.9	34	57.2	9.1	33	9.1	10.7
control	40	47.8	10.6	38	48.9	14.1	38	0.9	9.0
Therapy five levels at baseline									
.	12	48.8	10.1	13	58.8	10.3	12	9.3	9.4
5-ASA+-topical 5asa	46	49.5	10.5	43	54.5	12.1	43	4.6	11.2
immunomodulators (AZA+-MTX)	10	44.8	7.3	10	46.5	12.1	10	1.7	8.8
Biologicals	6	37.3	6.1	6	38.7	8.2	6	1.3	9.5
Disease activity (relapse) baseline yes no									
yes	12	43.2	10.0	12	45.6	12.5	12	2.4	14.7
no	62	48.7	10.1	60	54.3	12.2	59	5.2	9.6

NOTE: All IBDQ results on 0-100 scale (0 worst, 100 best)

NOTE: Signed rank test for change (from zero) in IBDQ: **p=0.0002** (FODMAP: p<0.001, Control: p=0.540)

NOTE: Wilcoxon rank test for TREATMENT influence on  $\Delta$ IBDQ: **p=0.0004**

NOTE: Wilcoxon rank test for TREATMENT allocation on IBDQ: **p=0.875**



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 9 of 77

CD only	HBI sum of all q at baseline			HBI sum of all q at end			Dif HBI		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
All	21	6.5	4.1	22	4.9	4.0	21	-1.5	2.4
Age 35									
<=35	10	5.2	5.1	10	3.9	4.7	10	-1.3	2.4
> 35	11	7.6	2.8	12	5.8	3.3	11	-1.6	2.4
IBD duration									
.	0	.	.	0	.	.	0	.	.
<=5 y	5	5.8	2.4	6	5.7	2.2	5	0.4	0.9
> 5 y	16	6.7	4.6	16	4.6	4.5	16	-2.1	2.4
Gender									
male	5	7.4	2.7	5	5.2	3.2	5	-2.2	3.1
female	16	6.2	4.5	17	4.8	4.3	16	-1.3	2.1
Intestinal surgery yes vs. no									
yes	8	6.1	4.5	8	3.8	4.4	8	-2.4	2.4
no	13	6.7	4.0	14	5.6	3.7	13	-0.9	2.2
Smoking									
never	11	5.6	4.8	12	4.9	4.3	11	-0.5	1.8
former smoker	7	7.0	3.8	7	4.1	4.4	7	-2.9	3.0
currently	3	8.3	1.2	3	6.7	0.6	3	-1.7	1.5
Diagnosis type									
CD	21	6.5	4.1	21	5.0	4.0	21	-1.5	2.4
UC	0	.	.	1	3.0	.	0	.	.
Treatment group FODMAP Kontrol									
intervention	9	5.9	2.9	9	3.3	2.6	9	-2.6	2.9
control	12	6.9	4.9	13	6.0	4.5	12	-0.7	1.5
Therapy five levels at baseline									
.	10	4.1	2.9	10	2.8	2.5	10	-1.3	2.4
5-ASA+-topical 5asa	2	6.0	4.2	3	3.3	3.5	2	-2.5	0.7
immunomodulators (AZA+-MTX)	7	8.6	4.0	7	7.1	3.6	7	-1.4	2.9
Biologicals	2	11.5	3.5	2	10.0	5.7	2	-1.5	2.1
Disease activity (relapse) baseline yes no									
Yes	1	9.0	.	2	6.0	4.2	1	0.0	.
No	20	6.4	4.2	20	4.8	4.0	20	-1.6	2.4
CD phenotype									
.	0	.	.	1	3.0	.	0	.	.
B1 inflammatory	14	5.6	4.5	14	4.7	4.3	14	-0.9	1.7
B2 stricturing	6	8.7	2.7	6	5.7	4.2	6	-3.0	3.2
B3 penetrating	1	5.0	.	1	5.0	.	1	0.0	.

NOTE: Signed rank test for change (from zero) in HBI: **p=0.008** (FODMAP: p=0.047, Control: p=0.250)

NOTE: Wilcoxon rank test for TREATMENT influence on ΔHBI: **p=0.097**

NOTE: Wilcoxon rank test for TREATMENT allocation on HBI1: **p=0.617**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 10 of 77

UC only	SCCAI som of all q at baseline			SCCAI sum of all q at the end			Dif SCCA1		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
All	53	2.5	1.8	53	2.1	2.3	53	-0.4	2.2
Age 35									
<=35	13	2.5	1.9	13	3.1	3.1	13	0.6	3.2
> 35	40	2.5	1.9	40	1.8	1.9	40	-0.7	1.7
IBD duration									
.	1	3.0	.	1	2.0	.	1	-1.0	.
<=5 y	26	2.6	1.8	26	2.8	2.4	26	0.2	2.5
> 5 y	26	2.4	2.0	26	1.5	2.0	26	-0.9	1.7
Gender									
male	13	2.1	1.9	13	1.5	2.3	13	-0.5	1.8
female	40	2.6	1.8	40	2.3	2.3	40	-0.3	2.3
Intestinal surgery yes vs. no									
yes	0	.	.	0	.	.	0	.	.
no	53	2.5	1.8	53	2.1	2.3	53	-0.4	2.2
Smoking									
never	31	2.7	1.8	31	2.4	2.6	31	-0.3	2.2
former smoker	19	2.4	1.8	19	1.5	1.5	19	-0.8	1.8
currently	3	1.3	2.3	3	3.0	3.0	3	1.7	3.8
Diagnosis type									
CD	0	.	.	0	.	.	0	.	.
UC	53	2.5	1.8	53	2.1	2.3	53	-0.4	2.2
Treatment group FODMAP Kontrol									
intervention	24	2.6	1.8	24	1.9	2.3	24	-0.7	2.6
control	29	2.4	1.9	29	2.3	2.3	29	-0.1	1.8
UC_extent									
.	0	.	.	0	.	.	0	.	.
pancolitis	14	2.2	1.9	14	1.6	2.4	14	-0.6	2.1
left sided	22	3.0	1.7	22	2.8	2.4	22	-0.2	2.6
proctosigmoiditis	17	2.1	1.9	17	1.7	2.0	17	-0.4	1.7
NA	0	.	.	0	.	.	0	.	.
Therapy five levels at baseline									
.	3	2.3	1.2	3	1.0	1.0	3	-1.3	1.5
5-ASA+-topical 5asa	45	2.5	1.8	45	2.1	2.2	45	-0.4	2.0
immunomodulators (AZA+-MTX)	2	2.5	3.5	2	3.0	4.2	2	0.5	7.8
Biologicals	3	3.0	2.6	3	3.3	3.5	3	0.3	1.5

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 11 of 77

UC only	SCCAI som of all q at baseline			SCCAI sum of all q at the end			Dif SCCA1		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
Disease activity (relapse) baseline yes no									
yes	10	2.5	2.1	10	3.9	3.3	10	1.4	3.5
no	43	2.5	1.8	43	1.7	1.8	43	-0.8	1.6

NOTE: Signed rank test for change (from zero) in SCCAI: p=0.139 (FODMAP: p=0.039, Control: p=0.984)

NOTE: Wilcoxon rank test for TREATMENT influence on ΔSCCAI: p=0.021

NOTE: Wilcoxon rank test for TREATMENT allocation on SCCAI 1: p=0.758

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 12 of 77

	Stools1			Stools2			Dif_stools		
	N	Mean	Std	N	Mean	Std	N	Mean	Std
All	74	3.5	1.9	74	3.2	2.0	74	-0.3	1.2
Age 35									
<=35	23	2.7	2.1	23	2.5	2.5	23	-0.3	1.5
> 35	51	3.8	1.7	51	3.5	1.7	51	-0.3	1.1
IBD duration									
.	1	3.0	.	1	3.0	.	1	0.0	.
<=5 y	31	3.5	1.6	31	3.6	1.6	31	0.1	1.2
> 5 y	42	3.5	2.1	42	2.9	2.3	42	-0.5	1.2
Gender									
male	18	3.2	1.3	18	3.2	1.8	18	0.0	1.1
female	56	3.6	2.1	56	3.2	2.1	56	-0.4	1.3
Intestinal surgery yes vs. no									
yes	8	3.0	3.7	8	2.3	3.9	8	-0.8	0.7
no	66	3.5	1.6	66	3.3	1.7	66	-0.2	1.3
Smoking									
never	42	3.4	1.9	42	3.1	1.9	42	-0.3	1.2
former smoker	26	3.7	2.1	26	3.5	2.4	26	-0.2	1.4
currently	6	3.5	0.8	6	3.0	0.6	6	-0.5	0.8
Diagnosis type									
CD	21	2.8	2.8	21	2.0	2.9	21	-0.8	1.1
UC	53	3.7	1.3	53	3.7	1.3	53	-0.1	1.2
Treatment group FODMAP Kontrol									
intervention	33	3.2	1.5	33	2.8	1.7	33	-0.4	1.2
control	41	3.7	2.1	41	3.5	2.2	41	-0.2	1.2
Therapy five levels at baseline									
.	13	2.2	2.1	13	1.7	2.1	13	-0.5	1.1
5-ASA+-topical 5asa	47	3.6	1.3	47	3.5	1.4	47	-0.1	1.2
immunomodulators (AZA+-MTX)	9	3.9	3.3	9	2.9	3.5	9	-1.0	1.3
Biologicals	5	5.2	1.6	5	4.8	2.2	5	-0.4	0.9
Disease activity (relapse) baseline yes no									
yes	11	4.4	1.6	11	4.5	1.8	11	0.1	1.5
no	63	3.3	1.9	63	3.0	2.0	63	-0.3	1.2

NOTE: Signed rank test for change (from zero) in

#Stools: **p=0.087**

NOTE: Wilcoxon rank test for TREATMENT influence on

ΔStools: **p=0.260**

NOTE: Wilcoxon rank test for TREATMENT influence on baseline

#Stools: **p=0.476**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 13 of 77

Table of TREAT by Stool_RESPONDER			
Treatment group	Stool_RESPONDER		
Frequency Row Pct	No	Yes	Total
FODMAP	25 75.76	8 24.24	33 100%
Control	35 85.37	6 14.63	41 100%
Total	60	14	74
Frequency Missing = 4			

Stool\_Responder: reduction (> 0) in #stools per day. **Fisher p-value=0.375**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 14 of 77

**Table2: Distribution of IBS\_QOL DOMAIN scores at baseline and the difference. 108 patients.**

Baseline domain-QOLs	All		
	N	Mean	Std
QOL1	77	69.3	19.8
Dysphoria1	77	72.1	24.4
Interference_activity1	77	61.5	24.4
Body_image1	77	65.5	23.2
Health_worry1	77	68.4	22.0
Food_avoidance1	77	57.5	27.6
Social_reaction1	77	78.6	18.6
Sexual1	77	76.3	26.1
Relationship1	77	81.2	18.4

NOTE: All IBS-QOL results and DOMAIN scores on 0-100 scale (0 worst, 100 best)

Change in domain-QOLs	Treatment									Treatment difference
	All			intervention			control			
	N	Mean	Std	N	Mean	Std	N	Mean	Std	p-value
Dif QOL	77	3.4	11.4	36	6.4	11.2	41	0.8	11.0	0.091
Dif Dysphoria	77	3.9	14.6	36	7.4	13.0	41	0.8	15.4	0.124
Dif interference	77	5.8	15.1	36	8.6	16.7	41	3.3	13.2	0.329
Dif body image	77	6.5	16.2	36	11.3	18.0	41	2.3	13.3	0.104
Dif health worry	77	1.4	14.8	36	3.7	14.6	41	-0.6	15.0	0.426
Dif food avoidance	77	-0.0	20.3	36	3.7	23.1	41	-3.3	17.2	0.240
Dif social	77	1.8	11.7	36	2.6	11.8	41	1.1	11.7	0.528
Dif sexual	77	1.1	19.1	36	5.6	16.8	41	-2.7	20.4	0.094
Dif relationship	77	1.4	15.3	36	3.0	15.6	41	0.0	15.0	0.502

NOTE: All change in IBS-QOL results and DOMAIN scores on -100 to +100 scale (-100 worst, 100 best)

NOTE: Kruskal-Wallis rank test used for test for TREATMENT differences in Dif\_domain\_QOLs

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 15 of 77

**Table3: IBS-SSS categories at baseline versus at week 6**

IBS_SSS categories at baseline and 6 weeks	SSScat2			
	1	2	3	4
SSScat1				
1	1	1	.	.
2	7	7	1	.
3	13	14	10	2
4	4	4	6	8

IBS_SSS categories at baseline and 6 weeks		SSScat2			
		1	2	3	4
SSScat1					
FODMAP	2	5	3	.	.
	3	8	10	2	1
	4	3	1	2	2
control	1	1	1	.	.
	2	2	4	1	.
	3	5	4	8	1
	4	1	3	4	6

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 16 of 77

**Table4: SCCAI categories at baseline versus at week 6**

IBD-IBS SCCAI categories at baseline and 6 weeks	SCCAI2cat		
	1	2	3
SCCAI1cat			
1	24	1	2
2	12	10	4

IBD-IBS SCCAI categories at baseline and 6 weeks		SCCAI2cat		
		1	2	3
Treatment group:	SCCAI1cat			
Intervention FODMAP	1	9	.	2
	2	8	5	.
control	1	15	1	.
	2	4	5	4





Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 17 of 77

**Table5: HBI categories at baseline versus at week 6**

HBI categories at baseline and 6 weeks, Crohn	HBI2cat		
	1	2	3
HBI1cat			
1	7	1	.
2	1	4	.
3	2	2	4

HBI categories at baseline and 6 weeks, Crohn		HBI2cat		
		1	2	3
Treatment group	HBI1cat			
Intervention FODMAP	1	3	1	.
	2	1	1	.
	3	2	1	.
control	1	4	.	.
	2	.	3	.
	3	.	1	4

Figure1: IBS-SSS, IBS-QOL and IBDQ cumulative distributions



Cumulative distribution of CHANGE in IBDQ





Figure2: Change in IBS-SSS



IBS-SSS: Change from baseline versus baseline, according to TREATMENT

Slope: in FODMAP group = -0.370 (p=0.204)per IBS-SSS point, in Control = -0.258 (p=0.148)






Figure3: Change in IBS-QOL



IBS-QOL: Change from baseline versus baseline.



No trends






Figure4: Change in IBDQ



IBDQ: Change from baseline versus baseline.





Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 25 of 77

Slope: in FODMAP group = -0.655 (p<0.0001) per IBDQ point, in Control no trend




Figure5: Change in IBS-QOL versus change in IBS-SSS









Figure6: Change in IBDQ, SCCAI and HBI versus change in IBS-SSS










Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 28 of 77

Figure8: histograms and box-plots











Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 33 of 77

**Table6: IBS-SSS at baseline: analysis of COVARIANCE:**

Effect	contrast	Base_SSS	Lower	Upper	p_value
AGE35	Below 35 years vs. above	-0.8267	-50.2095	48.5561	0.9734
Surgery	No vs. Yes	-2.7180	-71.4656	66.0296	0.9373
Smoking	Current vs. never	24.7991	-50.7632	100.36	0.5143
Smoking	Former vs. never	-45.9699	-94.2314	2.2915	0.0616
IBD durati	Below 5 years vs. above	17.7854	-26.4900	62.0608	0.4251
BMI	Per kg/m2	4.8733	0.9006	8.8460	0.0170
Gender	Females versus males	-18.8401	-68.8870	31.2068	0.4547
Diagnosis	CD vs. UC	14.9744	-62.6425	92.5912	0.7011
Treat BL	5ASA vs none	15.9644	-60.6712	92.6001	0.6786
Treat BL	Biol, vs none	44.6553	-51.7537	141.06	0.3582
Treat BL	Immuno vs none	-27.6723	-108.14	52.7963	0.4945
Remission	No vs. Yes	-15.7730	-88.2969	56.7509	0.6653

The baseline IBS-SSS is considered a continuous dependent variable and is treated using a linear normal analysis of covariance (ANCOVA) with covariates: Treatment at baseline, Gender, Age35, Smoking status, UC/CD, Surgery before baseline, years since IBD diagnosis and BMI. Note that BMI is used as regression variable.

**Table7: IBS-SSS CHANGE from baseline to week 6: analysis of COVARIANCE:**

Effect	contrast	DIFF_SSS	Lower	Upper	p_value
AGE35	Below 35 years vs. above	-15.3461	-64.9733	34.2811	0.5387
BMI	Per kg/m2	0.5765	-3.5823	4.7353	0.7826
Diagnosis	CD vs. UC	42.2110	-37.4614	121.88	0.2936
Gender	Females versus males	56.5868	5.0359	108.14	0.0320
IBD durati	Below 5 years vs. above	74.8855	30.3585	119.41	0.0013
Remission	No vs. Yes	10.0398	-62.7692	82.8488	0.7837
SSS1	Per baseline SSS point	-0.3607	-0.6138	-0.1076	0.0060
Smoking	Current vs. never	-0.6175	-81.2694	80.0344	0.9878
Smoking	Former vs. never	-10.1784	-60.2929	39.9361	0.6861
Surgery	No vs. Yes	-8.9781	-81.0389	63.0826	0.8041
TREAT	Control vs. FODMAP	35.4199	-12.6121	83.4518	0.1455
Treat BL	5ASA vs none	22.0404	-55.5412	99.6221	0.5721
Treat BL	Biol, vs none	71.1321	-25.9061	168.17	0.1478
Treat BL	Immuno vs none	61.1329	-20.8162	143.08	0.1409

The change in IBS-SSS is analyzed using the same model, EXCEPT for the inclusion of the baseline IBS-SSS value as regression variable and **the Treatment effect.**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 34 of 77

**Table8: IBS-QOL at baseline: analysis of COVARIANCE**

Effect	contrast	Base_QOL	Lower	Upper	p_value
AGE35	Below 35 years vs. above	-3.4307	-13.8653	7.0038	0.5135
Surgery	No vs. Yes	5.7750	-8.4781	20.0281	0.4211
Smoking	Current vs. never	-6.5035	-22.1669	9.1599	0.4097
Smoking	Former vs. never	4.3269	-5.7015	14.3552	0.3917
IBD durati	Below 5 years vs. above	-2.9140	-12.1220	6.2939	0.5293
BMI	Per kg/m2	-1.0135	-1.8435	-0.1835	0.0175
Gender	Females versus males	-8.4227	-19.0987	2.2533	0.1199
Diagnosis	CD vs. UC	0.03362	-16.1953	16.2626	0.9967
Treat BL	5ASA vs none	1.1028	-14.7902	16.9958	0.8901
Treat BL	Biol, vs none	-14.8155	-34.8016	5.1706	0.1435
Treat BL	Immuno vs none	4.2801	-12.4000	20.9601	0.6098
Remission	No vs. Yes	7.9238	-7.2705	23.1181	0.3012

The baseline IBS-QOL is considered a continuous dependent variable and is treated using a linear normal analysis of covariance with covariates: Treatment at baseline, Gender, Age35, Smoking status, UC/CD, Surgery before baseline, years since IBD diagnosis and BMI. Note that BMI is used as regression variable.

**Table9: IBS-QOL CHANGE from baseline to week 6: analysis of COVARIANCE:**

Effect	contrast	DIFF_QOL	Lower	Upper	p_value
AGE35	Below 35 years vs. abo	1.5245	-4.7749	7.8239	0.6301
BMI	Per kg/m2	-0.1193	-0.6449	0.4063	0.6515
Diagnosis	CD vs. UC	4.1235	-5.8474	14.0945	0.4114
Gender	Females versus males	-1.5733	-8.2510	5.1043	0.6391
IBD durati	Below 5 years vs. abov	-5.9934	-11.5375	-0.4493	0.0346
QOL1	Per baseline QOL point	-0.1067	-0.2604	0.04687	0.1697
Remission	No vs. Yes	-3.0951	-12.3250	6.1347	0.5049
Smoking	Current vs. never	-5.1380	-15.1309	4.8549	0.3079
Smoking	Former vs. never	0.1434	-6.0271	6.3138	0.9631
Surgery	No vs. Yes	2.9482	-6.0300	11.9263	0.5138
<b>TREAT</b>	<b>Control vs. FODMAP</b>	<b>-5.0737</b>	<b>-11.1045</b>	<b>0.9570</b>	<b>0.0976</b>
Treat BL	5ASA vs none	0.09978	-9.5514	9.7509	0.9836
Treat BL	Biol, vs none	-11.0651	-23.2961	1.1659	0.0754
Treat BL	Immuno vs none	-9.5449	-19.7021	0.6124	0.0650

The change in IBS-QOL is analyzed using the same model, EXCEPT for the inclusion of the baseline IBS-QOL value as regression variable and **the Treatment effect.**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 35 of 77

**Table10: IBDQ at baseline: analysis of COVARIANCE**

Effect	contrast	Base_IBDQ	Lower	Upper	p_value
AGE35	Below 35 years vs. above	-3.2168	-8.9530	2.5194	0.2663
Surgery	No vs. Yes	1.1180	-6.8151	9.0511	0.7789
Smoking	Current vs. never	-1.9516	-11.1219	7.2186	0.6718
Smoking	Former vs. never	0.3775	-5.2615	6.0165	0.8939
IBD durati	Below 5 years vs. above	-1.4127	-6.5975	3.7721	0.5877
BMI	Per kg/m2	-0.4807	-0.9269	-0.03447	0.0352
Gender	Females versus males	-1.9207	-8.0959	4.2544	0.5361
Diagnosis	CD vs. UC	1.3908	-7.5034	10.2851	0.7555
Treat BL	5ASA vs none	0.9423	-8.1964	10.0811	0.8372
Treat BL	Biol, vs none	-8.9282	-20.3432	2.4869	0.1229
Treat BL	Immuno vs none	-2.5458	-12.2384	7.1468	0.6012
Remission	No vs. Yes	1.8135	-6.4084	10.0354	0.6606

The baseline IBDQ is considered a continuous dependent variable and is treated using a linear normal analysis of covariance (ANCOVA) with covariates: Treatment at baseline, Gender, Age35, Smoking status, UC/CD, Surgery before baseline, years since IBD diagnosis and BMI. Note that BMI is used as regression variable.

**Table11: Change from baseline in IBDQ: analysis of COVARIANCE**

Effect	contrast	DIFF_IBDQ	Lower	Upper	p_value
AGE35	Below 35 years vs. abov	-0.02407	-5.5038	5.4557	0.9930
BMI	Per kg/m2	-0.4029	-0.8337	0.02791	0.0662
Diagnosis	CD vs. UC	-7.6271	-15.9992	0.7450	0.0733
Gender	Females versus males	-3.9016	-9.8336	2.0303	0.1928
IBD durati	Below 5 years vs. above	-5.4823	-10.2784	-0.6862	0.0258
IBDQ1	Per baseline IBDQ point	-0.4684	-0.7097	-0.2272	0.0003
Remission	No vs. Yes	4.5563	-3.1595	12.2722	0.2416
Smoking	Current vs. never	-0.4721	-9.1763	8.2321	0.9138
Smoking	Former vs. never	0.4826	-4.8305	5.7957	0.8562
Surgery	No vs. Yes	0.2092	-7.3633	7.7816	0.9560
<b>TREAT</b>	<b>Control vs. FODMAP</b>	<b>-6.1812</b>	<b>-11.2759</b>	<b>-1.0864</b>	<b>0.0183</b>
Treat BL	5ASA vs none	-8.7899	-17.1461	-0.4337	0.0396
Treat BL	Biol, vs none	-11.8607	-22.4483	-1.2732	0.0288
Treat BL	Immuno vs none	-6.3184	-15.2016	2.5647	0.1596

The change in IBDQ is analyzed using the same model, EXCEPT for the inclusion of the baseline IBDQ value as regression variable and **the Treatment effect.**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 36 of 77

**Table12: IBS-SSS responder analysis**

# RESPONDER:

Defining an IBS-SSS RESPONDER as a subject having at least 50 IBS-SSS points drop (maximum from 500 down to 0 ) during study, a logistic regression is used to evaluate which factors influence the chance (OR) of response

Effect	Response-OR	lower	upper	p-value
SSS1	1.003	0.997	1.010	0.2971
AGE35 0 vs 1	0.850	0.231	3.128	0.8067
SURG no vs yes	0.947	0.131	6.859	0.9571
Smoking currently vs never	2.816	0.198	40.042	0.4446
Smoking former smoker vs never	0.901	0.246	3.297	0.8754
IBD_DUR5 0 vs 1	0.298	0.088	1.010	0.0519
BMI	0.974	0.877	1.082	0.6229
Gender female vs male	0.649	0.154	2.743	0.5569
Diagnosis CD vs UC	1.052	0.117	9.447	0.9636
TREAT control vs intervention	0.201	0.055	0.731	0.0149
TBL 5ASA vs None	2.008	0.222	18.155	0.5349
TBL Biol. vs None	0.383	0.030	4.876	0.4600
TBL Immuno vs None	0.628	0.070	5.593	0.6764
relapse_BL no vs yes	0.418	0.061	2.860	0.3737

Based on the factors/covariates from the table right above, backward elimination is used to retain factors of importance. The baseline, SSS1, is forced into the model. **NOTE: the last line in the table below is just the OR-inversion (1/x) of the second-last line (interchanging the order of the two treatments involved):**

Effect	Response-OR	lower	upper	p-value
SSS1, per SSS baseline point	1.003	0.997	1.009	0.3317
IBD duration < 5y	0.390	0.137	1.111	0.0779
Control vs FODMAP	0.189	0.064	0.554	0.0024
<b>FODMAP vs control</b>	<b>5.29</b>	<b>1.81</b>	<b>15.63</b>	<b>0.0024</b>

**This reduced model is then applied to each of the five components of the SSS:**

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 37 of 77

#### Q1\_RESPONDER:

Effect	Response-OR	lower	upper	p-value
SSS1, per baseline point	1.009	1.002	1.015	0.0056
IBD duration < 5y	0.225	0.077	0.658	0.0065
Control vs FODMAP	0.586	0.213	1.610	0.3003

**Component 1 of the IBS-SSS: a RESPONDER is a subject having at least 10 IBS-SSS Q1 points drop (maximum from 100 down to 0 ) during study**

#### Q2\_RESPONDER:

Effect	Response-OR	lower	upper	p-value
SSS1, per baseline point	1.006	1.000	1.012	0.0373
IBD duration < 5y	0.717	0.270	1.900	0.5031
Control vs FODMAP	0.337	0.127	0.895	0.0290

#### Q3\_RESPONDER:

Effect	Response-OR	lower	upper	p-value
SSS1, per baseline point	1.003	0.997	1.009	0.2623
IBD duration < 5y	0.377	0.131	1.081	0.0696
Control vs FODMAP	0.711	0.250	2.018	0.5212

#### Q4\_RESPONDER:

Effect	Response-OR	lower	upper	p-value
SSS1, per baseline point	0.999	0.994	1.004	0.7762
IBD duration < 5y	0.790	0.309	2.024	0.6239
Control vs FODMAP	0.411	0.163	1.034	0.0590

#### Q5\_RESPONDER:

Effect	Response-OR	lower	upper	p-value
SSS1, per baseline point	1.003	0.998	1.009	0.2369
IBD duration < 5y	0.328	0.122	0.884	0.0275
Control vs FODMAP	0.678	0.255	1.803	0.4364

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 38 of 77

**Table13: Distribution of FC, CRP and FODMAPS at baseline, week 6 and the difference.**

	FC baseline				FC END				D_FC			
	N	Mean	Std	Median	N	Mean	Std	Median	N	Mean	Std	Median
All	73	210.6	359.4	43.0	68	158.9	293.2	43.5	68	-37.0	246.5	3.0
Age 35												
<=35	24	241.7	435.9	33.0	23	196.6	302.6	66.0	23	-53.9	236.0	4.0
> 35	49	195.3	319.3	47.0	45	139.6	289.8	40.0	45	-28.4	253.8	3.0
IBD duration												
.	1	5.0	.	5.0	1	7.0	.	7.0	1	2.0	.	2.0
<=5 y	30	268.2	436.1	42.0	29	228.0	371.5	90.0	29	-48.1	332.9	6.0
> 5 y	42	174.3	295.8	48.0	38	110.1	210.7	38.5	38	-29.6	161.0	2.5
Gender												
male	18	399.5	525.9	146.5	16	287.0	477.3	103.5	16	-62.6	356.8	3.0
female	55	148.7	263.3	40.0	52	119.4	197.9	38.5	52	-29.2	205.2	3.0
Intestinal surgery yes vs. no												
yes	10	167.3	163.6	114.0	9	116.2	131.9	49.0	9	-50.3	150.9	10.0
no	63	217.4	381.8	41.0	59	165.4	310.7	40.0	59	-35.0	258.8	3.0
Smoking												
never	41	267.0	431.6	49.0	37	224.4	373.7	66.0	37	-22.4	264.5	2.0
former smoker	26	140.0	238.5	34.5	26	75.8	118.5	34.5	26	-64.2	234.7	3.0
currently	6	131.0	160.2	48.5	5	105.6	81.1	117.0	5	-3.6	187.9	5.0
Diagnosis type												
CD	20	254.4	408.5	46.0	19	148.7	183.6	48.0	19	-83.0	288.5	5.0
UC	53	194.1	341.8	41.0	49	162.8	327.5	38.0	49	-19.2	229.0	2.0
Treatment group FODMAP Kontrol												
intervention	36	203.0	312.6	50.5	34	158.9	306.7	48.5	34	-43.9	263.6	3.0
control	37	217.9	404.0	39.0	34	158.9	283.6	34.0	34	-30.1	231.8	3.0
Therapy five levels at baseline												
.	13	53.6	74.0	30.0	12	82.5	128.8	39.0	12	38.9	78.6	9.0
5-ASA+-topical 5asa+-topical_ster	47	189.8	328.4	43.0	44	145.0	257.2	49.0	44	-30.6	195.8	1.5
immunomodulators (AZA+-MTX)	9	436.7	550.5	186.0	8	210.6	231.4	153.5	8	-195	410.6	-26.5
Biologicals with any of aboth combination	4	456.0	518.2	389.0	4	436.5	805.7	38.5	4	-19.5	547.9	17.0
Disease activity (relapse) baseline yes no												
yes	10	709.3	614.2	688.5	10	563.6	563.8	366.5	10	-146	519.4	4.0
no	63	131.4	220.8	39.0	58	89.1	130.9	38.5	58	-18.3	162.4	3.0

NOTE: Signed rank test for change (from zero) in # FC: p=0.882  
NOTE: Wilcoxon rank test for TREATMENT influence on Δ FC: p=0.825  
NOTE: Wilcoxon rank test for TREATMENT influence on baseline FC: p=0.277

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 39 of 77

	CRP at baseline				CRP at end				D_CRP			
	N	Mean	Std	Median	N	Mean	Std	Median	N	Mean	Std	Median
All	78	4.2	7.5	2.0	78	3.1	5.3	2.0	78	-1.0	6.2	0.0
Age 35												
<=35	26	3.4	3.9	2.0	26	3.9	5.8	2.0	26	0.5	7.2	0.0
> 35	52	4.5	8.8	2.0	52	2.8	5.0	2.0	52	-1.7	5.7	0.0
IBD duration												
.	1	2.0	.	2.0	1	2.0	.	2.0	1	0.0	.	0.0
<=5 y	32	3.6	4.6	2.0	32	3.3	5.3	2.0	32	-0.3	7.2	0.0
> 5 y	45	4.6	9.1	2.0	45	3.0	5.4	2.0	45	-1.5	5.6	0.0
Gender												
male	19	7.1	13.3	2.0	19	5.0	8.6	2.0	19	-2.1	8.6	0.0
female	59	3.2	4.0	2.0	59	2.6	3.6	2.0	59	-0.7	5.3	0.0
Intestinal surgery yes vs. no												
yes	12	5.6	9.5	2.0	12	3.0	1.5	2.0	12	-2.6	9.1	0.0
no	66	3.9	7.1	2.0	66	3.2	5.7	2.0	66	-0.7	5.6	0.0
Smoking												
never	44	4.4	8.3	2.0	44	3.8	7.0	2.0	44	-0.5	6.4	0.0
former smoker	27	3.5	6.4	2.0	27	2.2	0.7	2.0	27	-1.3	6.1	0.0
currently	7	5.4	6.3	2.0	7	2.6	1.5	2.0	7	-2.9	6.0	0.0
Diagnosis type												
CD	23	7.4	12.4	2.0	23	4.0	7.5	2.0	23	-3.4	7.7	0.0
UC	55	2.8	3.3	2.0	55	2.8	4.1	2.0	55	0.0	5.3	0.0
Treatment group FODMAP Control												
intervention	37	4.0	6.1	2.0	37	3.5	5.0	2.0	37	-0.5	7.8	0.0
control	41	4.3	8.6	2.0	41	2.9	5.6	2.0	41	-1.4	4.4	0.0
Therapy five levels at baseline												
.	14	3.6	4.5	2.0	14	2.2	0.8	2.0	14	-1.4	4.7	0.0
5-ASA+-topical 5asa+-topical_ster	47	2.9	3.6	2.0	47	2.9	4.4	2.0	47	0.0	5.7	0.0
immunomodulators (AZA+-MTX)	10	11.4	17.7	2.0	10	5.9	11.3	2.0	10	-5.5	10.3	0.0
Biologicals with any of aboth combination	7	3.1	2.3	2.0	7	2.4	1.1	2.0	7	-0.7	2.4	0.0
Disease activity (relapse) baseline yes no												
yes	13	3.9	4.6	2.0	13	4.3	7.5	2.0	13	0.4	9.0	0.0
No	65	4.2	8.0	2.0	65	2.9	4.8	2.0	65	-1.3	5.6	0.0

NOTE: Signed rank test for change (from zero) in

CRP: p=0.097

NOTE: Wilcoxon rank test for TREATMENT influence on

Δ CRP: p=0.239

NOTE: Wilcoxon rank test for TREATMENT influence on baseline

CRP: p=0.321

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 40 of 77

	FODMAPS at baseline				FODMAPS at end				D_FODMAPS			
	N	Mean	Std	Median	N	Mean	Std	Median	N	Mean	Std	Median
All	78	27.6	14.1	24.0	73	17.2	15.9	14.0	73	-9.6	16.7	-7.0
Age 35												
<=35	26	27.7	14.1	24.2	24	17.0	18.5	14.1	24	-9.1	15.9	-2.1
> 35	52	27.6	14.3	23.9	49	17.3	14.6	14.0	49	-9.9	17.2	-7.0
IBD duration												
.	1	17.0	.	17.0	1	14.0	.	14.0	1	-3.0	.	-3.0
<=5 y	32	28.1	12.9	25.7	28	18.1	16.6	13.1	28	-7.8	11.9	-7.5
> 5 y	45	27.5	15.1	23.7	44	16.7	15.7	14.2	44	-10.9	19.4	-2.1
Gender												
male	19	25.6	12.4	23.0	19	15.8	15.7	10.0	19	-9.8	11.3	-7.9
female	59	28.3	14.6	24.0	54	17.7	16.0	15.0	54	-9.6	18.3	-2.4
Intestinal surgery yes vs. no												
Yes	12	29.3	14.8	25.2	11	8.9	14.6	2.0	11	-20.9	18.9	-20.0
No	66	27.3	14.1	23.7	62	18.7	15.7	15.9	62	-7.6	15.6	-2.4
Smoking												
never	44	28.3	15.7	24.0	41	22.2	17.0	20.9	41	-5.3	16.8	0.0
former smoker	27	25.6	10.6	23.7	26	11.8	12.0	7.7	26	-13.7	14.8	-12.2
currently	7	31.5	15.9	24.3	6	6.8	10.4	0.9	6	-21.6	16.1	-20.0
Diagnosis type												
CD	23	33.8	13.3	35.6	22	18.6	20.0	13.5	22	-14.5	18.1	-11.1
UC	55	25.0	13.7	21.4	51	16.6	13.9	14.0	51	-7.5	15.8	-2.6
Treatment group FODMAP Kontrol												
intervention	37	27.4	15.5	23.7	33	6.1	10.2	2.0	33	-19.6	16.7	-19.0
control	41	27.8	12.9	25.9	40	26.4	13.7	24.7	40	-1.4	11.6	0.0
Therapy five levels at baseline												
.	14	29.2	12.6	25.0	12	15.5	16.8	8.0	12	-12.5	15.3	-5.9
5-ASA+-topical 5asa+-topical_ster	47	25.3	14.7	21.3	44	16.2	14.2	13.9	44	-8.1	15.7	-2.4
immunomodulators (AZA+-MTX)	10	35.4	14.5	37.3	10	27.6	22.4	30.6	10	-7.8	24.7	-1.7
Biologicals with any of aboth combination	7	28.7	9.9	30.0	7	11.6	9.1	9.0	7	-17.1	11.1	-19.0
Disease activity (relapse) baseline yes no												
Yes	13	24.5	11.3	22.0	12	16.3	11.5	15.2	12	-6.0	14.4	-5.7
No	65	28.3	14.6	24.0	61	17.4	16.7	13.9	61	-10.3	17.1	-7.0

NOTE: Signed rank test for change (from zero) in FODMAPS: p<0.0001 in  
NOTE: Wilcoxon rank test for TREATMENT influence on  $\Delta$  FODMAPS: p<0.0001  
NOTE: Wilcoxon rank test for TREATMENT influence on baseline FODMAPS: p=0.532



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 41 of 77

**Table 14: FC and CRP categories (0/1) at baseline versus at week 6**

Cut point for FC in CD patients: 200

Cut point for FC in UC patients: 100

IBD-IBS FC categories at baseline and 6 weeks	FC2cat	
	0	1
FC1cat		
0	40	5
1	11	12


IBD-IBS FC categories at baseline and 6 weeks		FC2cat	
		0	1
Treatment group FODMAP Kontrol	FC1cat		
intervention	0	17	4
	1	7	6
control	0	23	1
	1	4	6


Cut point for CRP: 3

IBD-IBS CRP categories at baseline and 6 weeks	CRP2cat	
	0	1
CRP1cat		
0	64	3
1	5	6


IBD-IBS CRP categories at baseline and 6 weeks		CRP2cat	
		0	1
Treatment group FODMAP Kontrol	CRP1cat		
intervention	0	27	3
	1	3	4
control	0	37	.
	1	2	2

Figure 9: Scatterplots for SCCAI, HBI, FC, CRF and FODMAPS





FODMAPS: baseline versus end of study.



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 45 of 77

**Table 15: Detailed tables for endpoints according to Intervention/Control**

**Treatment intervention**

	SSS1						Dif SSS					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	37	232.3	78.8	210.0	90.0	454.0	37	-114	96.2	-102	-320	120.0
Age 35												
0	13	238.5	70.4	210.0	160.0	370.0	13	-110	97.2	-128	-260	120.0
1	24	229.0	84.3	225.0	90.0	454.0	24	-116	97.7	-101	-320	86.0
IBD duration												
0	15	238.8	85.4	210.0	115.0	454.0	15	-85.8	101.5	-90.0	-256	120.0
1	22	227.9	75.8	215.0	90.0	370.0	22	-133	89.8	-113	-320	10.0
Gender												
male	12	249.1	87.7	232.5	120.0	454.0	12	-133	101.1	-96.0	-320	10.0
female	25	224.2	74.7	210.0	90.0	370.0	25	-104	94.4	-110	-305	120.0
Intestinal surgery yes vs. no												
yes	10	238.2	83.4	225.0	120.0	370.0	10	-119	71.3	-105	-260	-2.0
no	27	230.1	78.6	210.0	90.0	454.0	27	-111	105.1	-102	-320	120.0
Smoking												
never	15	252.6	85.8	230.0	115.0	454.0	15	-115	112.3	-100	-305	120.0
former smoker	16	198.6	65.7	206.0	90.0	330.0	16	-120	83.3	-106	-320	10.0
currently	6	271.5	66.6	260.0	178.0	370.0	6	-91.3	99.0	-104	-216	86.0
Diagnosis type												
CD	11	227.5	83.0	210.0	120.0	370.0	11	-119	87.2	-115	-260	86.0
UC	26	234.3	78.6	225.0	90.0	454.0	26	-111	101.3	-95.0	-320	120.0
Therapy five levels at baseline												
.	8	240.3	69.7	215.0	160.0	370.0	8	-145	104.8	-169	-260	86.0
5-ASA+-topical 5asa+-topical_ster	22	218.7	66.4	220.0	90.0	330.0	22	-106	100.1	-96.0	-320	120.0
immunomodulators (AZA+-MTX)	3	206.0	102.9	178.0	120.0	320.0	3	-102	23.1	-92.0	-128	-85.0
Biologicals with any of aboth combination	4	311.0	121.6	290.0	210.0	454.0	4	-104	108.0	-78.0	-256	-2.0
Disease activity (relapse) baseline yes no												
yes	6	270.3	113.5	210.0	178.0	454.0	6	-70.3	125.6	-78.0	-256	120.0
no	31	224.9	70.4	220.0	90.0	370.0	31	-122	89.6	-110	-320	86.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 46 of 77

## Treatment control

	SSS1						Dif SSS					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	41	248.7	99.7	245.0	60.0	450.0	41	-68.1	95.2	-46.0	-282	100.0
Age 35												
0	13	268.5	93.3	260.0	90.0	400.0	13	-76.6	107.2	-40.0	-282	100.0
1	28	239.5	102.9	220.0	60.0	450.0	28	-64.1	90.9	-48.0	-280	96.0
IBD duration												
.	1	220.0	.	220.0	220.0	220.0	1	-31.0	.	-31.0	-31.0	-31.0
0	17	270.4	91.6	250.0	120.0	410.0	17	-40.6	94.4	-17.0	-230	100.0
1	23	233.8	106.5	245.0	60.0	450.0	23	-90.0	94.0	-60.0	-282	30.0
Gender												
male	7	264.3	105.0	290.0	120.0	410.0	7	-128	133.8	-116	-282	30.0
female	34	245.4	99.9	232.5	60.0	450.0	34	-55.8	82.6	-43.0	-230	100.0
Intestinal surgery yes vs. no												
yes	2	207.5	53.0	207.5	170.0	245.0	2	-11.0	15.6	-11.0	-22.0	0.0
no	39	250.8	101.5	250.0	60.0	450.0	39	-71.0	96.7	-49.0	-282	100.0
Smoking												
never	29	254.5	102.9	250.0	61.0	450.0	29	-71.7	99.6	-49.0	-282	100.0
former smoker	11	229.5	97.4	220.0	60.0	390.0	11	-54.8	89.5	-25.0	-220	96.0
currently	1	290.0	.	290.0	290.0	290.0	1	-110	.	-110	-110	-110
Diagnosis type												
CD	12	262.2	112.3	250.0	61.0	410.0	12	-23.3	63.9	-22.0	-116	100.0
UC	29	243.1	95.6	220.0	60.0	450.0	29	-86.6	100.6	-60.0	-282	96.0
Therapy five levels at baseline												
.	6	206.7	99.1	200.0	60.0	360.0	6	-34.5	38.6	-32.0	-102	5.0
5-ASA+-topical 5asa+-topical_ster	25	257.6	91.7	260.0	90.0	450.0	25	-97.8	102.1	-76.0	-282	96.0
immunomodulators (AZA+-MTX)	7	242.3	125.9	245.0	61.0	410.0	7	-8.6	69.9	-22.0	-116	100.0
Biologicals with any of aboth combination	3	273.3	135.8	290.0	130.0	400.0	3	-26.7	90.7	-40.0	-110	70.0
Disease activity (relapse) baseline yes no												
yes	7	261.4	92.5	260.0	130.0	410.0	7	-110	115.7	-114	-282	70.0
no	34	246.0	102.3	242.5	60.0	450.0	34	-59.4	89.9	-36.5	-280	100.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 47 of 77

Treatment intervention

	QOL1						Dif QOL					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	36	67.2	19.5	72.8	19.1	98.5	36	6.4	11.2	1.8	-8.8	36.0
Age 35												
0	12	62.7	18.5	64.7	27.2	94.1	12	7.5	10.5	5.5	-7.4	25.0
1	24	69.4	20.1	73.2	19.1	98.5	24	5.9	11.7	1.5	-8.8	36.0
IBD duration												
0	14	66.1	22.1	71.3	19.1	94.1	14	2.5	8.1	1.1	-8.8	25.0
1	22	67.8	18.3	73.2	27.2	98.5	22	8.9	12.3	4.0	-7.4	36.0
Gender												
male	11	72.8	23.0	78.7	19.1	98.5	11	4.7	12.3	0.0	-7.4	36.0
female	25	64.7	17.8	66.9	27.2	92.6	25	7.1	10.8	3.7	-8.8	32.4
Intestinal surgery yes vs. no												
yes	10	65.0	21.2	66.9	27.2	98.5	10	6.0	12.0	1.5	-7.4	32.4
no	26	68.0	19.2	72.8	19.1	94.1	26	6.6	11.1	1.8	-8.8	36.0
Smoking												
never	14	65.6	18.9	68.4	19.1	94.1	14	7.1	10.8	1.8	-4.4	28.7
former smoker	16	71.7	18.0	78.7	45.6	98.5	16	7.6	12.3	2.6	-7.4	36.0
currently	6	58.6	24.7	67.6	27.2	80.1	6	1.5	8.6	1.5	-8.8	11.8
Diagnosis type												
CD	11	62.0	22.8	62.5	27.2	98.5	11	7.4	12.8	2.9	-8.8	32.4
UC	25	69.4	17.9	72.8	19.1	94.1	25	6.0	10.6	1.5	-7.4	36.0
Therapy five levels at baseline												
.	8	59.8	17.9	61.4	28.7	80.1	8	11.0	13.4	9.6	-8.8	32.4
5-ASA+-topical 5asa+-topical_ster	21	73.9	14.3	73.5	45.6	94.1	21	6.9	11.0	2.2	-7.4	36.0
immunomodulators (AZA+-MTX)	3	68.6	37.0	80.1	27.2	98.5	3	1.0	8.9	0.0	-7.4	10.3
Biologicals with any of aboth combination	4	45.4	18.3	51.8	19.1	58.8	4	-1.3	2.1	-0.4	-4.4	0.0
Disease activity (relapse) baseline yes no												
yes	6	55.3	21.1	57.7	19.1	80.1	6	2.1	5.5	0.0	-4.4	10.3
no	30	69.5	18.7	73.2	27.2	98.5	30	7.3	11.8	2.6	-8.8	36.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 48 of 77

# Treatment control

	QOL1						Dif QOL					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	41	71.2	20.0	77.2	30.1	98.5	41	0.8	11.0	0.0	-41.2	23.5
Age 35												
0	13	64.5	20.5	66.2	30.1	96.3	13	3.3	9.9	2.2	-12.5	17.6
1	28	74.4	19.4	80.5	31.6	98.5	28	-0.4	11.4	0.0	-41.2	23.5
IBD duration												
.	1	88.2	.	88.2	88.2	88.2	1	-14.0	.	-14.0	-14.0	-14.0
0	17	69.2	19.2	77.9	31.6	95.6	17	-0.6	12.4	0.0	-41.2	14.7
1	23	72.0	21.1	77.2	30.1	98.5	23	2.4	9.7	0.7	-19.9	23.5
Gender												
male	7	79.2	22.2	86.0	32.4	95.6	7	3.6	6.7	1.5	-1.5	17.6
female	34	69.6	19.5	76.8	30.1	98.5	34	0.2	11.7	0.0	-41.2	23.5
Intestinal surgery yes vs. no												
yes	2	64.0	29.1	64.0	43.4	84.6	2	4.4	6.2	4.4	0.0	8.8
no	39	71.6	19.9	77.2	30.1	98.5	39	0.6	11.2	0.0	-41.2	23.5
Smoking												
never	29	69.2	20.5	77.2	30.1	96.3	29	1.2	9.4	1.5	-19.9	17.6
former smoker	11	76.5	19.6	83.8	42.6	98.5	11	-0.3	15.4	0.0	-41.2	23.5
currently	1	72.8	.	72.8	72.8	72.8	1	-2.2	.	-2.2	-2.2	-2.2
Diagnosis type												
CD	12	69.1	20.2	77.6	30.1	95.6	12	0.8	7.0	0.0	-10.3	14.7
UC	29	72.1	20.3	77.2	31.6	98.5	29	0.7	12.4	1.5	-41.2	23.5
Therapy five levels at baseline												
.	6	81.6	13.0	83.1	59.6	98.5	6	1.7	9.7	0.4	-14.0	14.7
5-ASA+-topical 5asa+-topical_ster	25	71.8	20.3	77.2	31.6	96.3	25	1.9	12.3	2.2	-41.2	23.5
immunomodulators (AZA+-MTX)	7	68.9	20.5	77.9	43.4	95.6	7	-3.9	9.2	-1.5	-19.9	8.8
Biologicals with any of aboth combination	3	51.5	21.3	51.5	30.1	72.8	3	-0.2	5.4	-2.2	-4.4	5.9
Disease activity (relapse) baseline yes no												
yes	7	62.3	20.1	58.8	32.4	90.4	7	2.7	12.1	4.4	-19.9	17.6
no	34	73.1	19.8	78.7	30.1	98.5	34	0.3	10.9	0.0	-41.2	23.5



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 49 of 77

# Treatment intervention

	IBDQ1						Dif IBDQ					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	34	47.8	9.9	47.0	30.0	68.0	33	9.1	10.7	6.0	-22.0	30.0
Age 35												
0	12	44.6	10.0	44.0	30.0	63.0	11	6.5	12.2	5.0	-22.0	22.0
1	22	49.5	9.6	50.0	34.0	68.0	22	10.4	9.9	7.5	-5.0	30.0
IBD duration												
0	13	49.5	8.3	47.0	33.0	63.0	12	3.2	10.4	2.5	-22.0	22.0
1	21	46.7	10.8	46.0	30.0	68.0	21	12.4	9.6	14.0	-5.0	30.0
Gender												
male	10	51.4	9.4	52.0	34.0	66.0	9	5.7	9.6	3.0	-2.0	30.0
female	24	46.3	9.8	45.0	30.0	68.0	24	10.3	11.0	12.0	-22.0	26.0
Intestinal surgery yes vs. no												
yes	9	44.9	8.6	45.0	30.0	55.0	9	9.6	7.7	6.0	0.0	23.0
no	25	48.8	10.2	47.0	33.0	68.0	24	8.9	11.8	7.5	-22.0	30.0
Smoking												
never	13	48.5	9.8	47.0	30.0	63.0	12	7.5	12.6	5.5	-22.0	26.0
former smoker	16	47.9	11.0	46.5	33.0	68.0	16	10.3	10.6	8.5	-5.0	30.0
currently	5	45.2	7.1	47.0	34.0	51.0	5	9.0	6.3	9.0	2.0	19.0
Diagnosis type												
CD	9	46.1	6.9	45.0	34.0	55.0	9	9.1	8.5	6.0	0.0	23.0
UC	25	48.4	10.8	47.0	30.0	68.0	24	9.0	11.6	9.0	-22.0	30.0
Therapy five levels at baseline												
.	6	45.0	5.3	43.5	40.0	55.0	6	15.8	9.1	19.5	4.0	24.0
5-ASA+-topical 5asa+-topical_ster	22	50.5	10.2	51.0	33.0	68.0	21	7.7	11.8	6.0	-22.0	30.0
immunomodulators (AZA+-MTX)	3	43.3	9.5	43.0	34.0	53.0	3	5.7	3.5	6.0	2.0	9.0
Biologicals with any of aboth combination	3	37.3	7.5	37.0	30.0	45.0	3	8.3	7.4	11.0	0.0	14.0
Disease activity (relapse) baseline yes no												
yes	5	42.4	10.0	43.0	30.0	57.0	5	2.4	14.6	9.0	-22.0	14.0
no	29	48.7	9.7	47.0	33.0	68.0	28	10.3	9.7	6.0	-5.0	30.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 50 of 77

Treatment control

	IBDQ1						Dif IBDQ					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	40	47.8	10.6	49.5	24.0	67.0	38	0.9	9.0	0.0	-22.0	24.0
Age 35												
0	13	44.5	11.4	45.0	24.0	60.0	12	2.9	10.9	2.0	-18.0	24.0
1	27	49.3	10.1	50.0	28.0	67.0	26	0.0	8.1	0.0	-22.0	22.0
IBD duration												
.	1	59.0	.	59.0	59.0	59.0	1	0.0	.	0.0	0.0	0.0
0	17	45.1	9.6	44.0	28.0	64.0	15	0.2	6.5	-1.0	-10.0	16.0
1	22	49.3	11.2	51.5	24.0	67.0	22	1.5	10.7	2.5	-22.0	24.0
Gender												
male	6	45.5	13.2	47.0	24.0	64.0	6	5.0	10.4	3.5	-6.0	24.0
female	34	48.2	10.3	49.5	28.0	67.0	32	0.2	8.7	0.0	-22.0	22.0
Intestinal surgery yes vs. no												
yes	2	50.5	9.2	50.5	44.0	57.0	2	-1.5	2.1	-1.5	-3.0	0.0
no	38	47.6	10.8	49.5	24.0	67.0	36	1.1	9.2	0.5	-22.0	24.0
Smoking												
never	28	46.8	9.8	49.5	24.0	60.0	27	1.4	10.3	0.0	-22.0	24.0
former smoker	11	50.6	12.9	51.0	28.0	67.0	10	0.3	4.1	1.0	-5.0	6.0
currently	1	43.0	.	43.0	43.0	43.0	1	-7.0	.	-7.0	-7.0	-7.0
Diagnosis type												
CD	12	45.1	10.1	47.0	28.0	58.0	12	-1.3	4.8	-1.0	-8.0	9.0
UC	28	48.9	10.8	49.5	24.0	67.0	26	1.9	10.3	2.5	-22.0	24.0
Therapy five levels at baseline												
.	6	52.7	12.7	57.5	28.0	63.0	6	2.8	3.4	2.0	0.0	9.0
5-ASA+-topical 5asa+-topical_ster	24	48.5	10.8	49.5	24.0	67.0	22	1.6	10.0	2.5	-22.0	24.0
immunomodulators (AZA+-MTX)	7	45.4	6.9	45.0	33.0	54.0	7	0.0	10.0	-3.0	-8.0	22.0
Biologicals with any of aboth combination	3	37.3	6.0	38.0	31.0	43.0	3	-5.7	5.1	-7.0	-10.0	0.0
Disease activity (relapse) baseline yes no												
yes	7	43.7	10.7	45.0	24.0	56.0	7	2.4	15.9	-1.0	-18.0	24.0
no	33	48.6	10.5	50.0	28.0	67.0	31	0.6	7.0	0.0	-22.0	16.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 51 of 77

# Treatment intervention

	SCCAI1						Dif SCCAI					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	24	2.6	1.8	3.0	0.0	5.0	24	-0.7	2.6	-1.0	-4.0	7.0
Age 35												
0	6	2.2	1.7	2.0	0.0	5.0	6	1.2	4.3	-0.5	-3.0	7.0
1	18	2.7	1.9	3.0	0.0	5.0	18	-1.3	1.4	-1.0	-4.0	0.0
IBD duration												
0	12	2.3	1.6	2.0	0.0	5.0	12	0.2	3.1	-1.0	-3.0	7.0
1	12	2.8	2.0	3.5	0.0	5.0	12	-1.6	1.6	-1.0	-4.0	0.0
Gender												
male	8	2.4	1.9	2.0	0.0	5.0	8	-1.4	1.3	-1.0	-4.0	0.0
female	16	2.7	1.8	3.0	0.0	5.0	16	-0.4	3.0	-1.0	-4.0	7.0
Intestinal surgery yes vs. no												
yes	0	.	.	.	.	.	0	.	.	.	.	.
no	24	2.6	1.8	3.0	0.0	5.0	24	-0.7	2.6	-1.0	-4.0	7.0
Smoking												
never	11	2.4	1.4	2.0	0.0	5.0	11	-0.5	2.8	-1.0	-4.0	7.0
former smoker	10	3.2	2.0	3.5	0.0	5.0	10	-1.6	1.4	-1.5	-4.0	0.0
currently	3	1.3	2.3	0.0	0.0	4.0	3	1.7	3.8	0.0	-1.0	6.0
Diagnosis type												
CD	0	.	.	.	.	.	0	.	.	.	.	.
UC	24	2.6	1.8	3.0	0.0	5.0	24	-0.7	2.6	-1.0	-4.0	7.0
Therapy five levels at baseline												
.	1	3.0	.	3.0	3.0	3.0	1	-3.0	.	-3.0	-3.0	-3.0
5-ASA+-topical 5asa+-topical_ster	20	2.8	1.8	3.0	0.0	5.0	20	-1.0	2.3	-1.0	-4.0	7.0
immunomodulators (AZA+-MTX)	1	0.0	.	0.0	0.0	0.0	1	6.0	.	6.0	6.0	6.0
Biologicals with any of aboth combination	2	2.0	2.8	2.0	0.0	4.0	2	-0.5	0.7	-0.5	-1.0	0.0
Disease activity (relapse) baseline yes no												
yes	4	1.3	1.9	0.5	0.0	4.0	4	3.0	4.1	3.0	-1.0	7.0
no	20	2.9	1.7	3.0	0.0	5.0	20	-1.5	1.4	-1.0	-4.0	0.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 52 of 77

# Treatment control

	SCCAI1						Dif SCCAI					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	29	2.4	1.9	2.0	0.0	5.0	29	-0.1	1.8	0.0	-5.0	3.0
Age 35												
0	7	2.7	2.1	3.0	0.0	5.0	7	0.1	2.3	0.0	-4.0	3.0
1	22	2.3	1.9	2.0	0.0	5.0	22	-0.1	1.7	0.0	-5.0	3.0
IBD duration												
.	1	3.0	.	3.0	3.0	3.0	1	-1.0	.	-1.0	-1.0	-1.0
0	14	2.8	1.9	3.0	0.0	5.0	14	0.3	2.0	0.0	-4.0	3.0
1	14	2.0	1.9	1.0	0.0	5.0	14	-0.4	1.7	0.0	-5.0	3.0
Gender												
male	5	1.6	2.1	1.0	0.0	5.0	5	0.8	1.6	0.0	-1.0	3.0
female	24	2.6	1.9	2.5	0.0	5.0	24	-0.3	1.8	0.0	-5.0	3.0
Intestinal surgery yes vs. no												
yes	0	.	.	.	.	.	0	.	.	.	.	.
no	29	2.4	1.9	2.0	0.0	5.0	29	-0.1	1.8	0.0	-5.0	3.0
Smoking												
never	20	2.9	2.0	3.0	0.0	5.0	20	-0.1	1.9	0.0	-5.0	3.0
former smoker	9	1.4	1.1	1.0	0.0	4.0	9	0.0	1.8	0.0	-3.0	3.0
currently	0	.	.	.	.	.	0	.	.	.	.	.
Diagnosis type												
CD	0	.	.	.	.	.	0	.	.	.	.	.
UC	29	2.4	1.9	2.0	0.0	5.0	29	-0.1	1.8	0.0	-5.0	3.0
Therapy five levels at baseline												
.	2	2.0	1.4	2.0	1.0	3.0	2	-0.5	0.7	-0.5	-1.0	0.0
5-ASA+-topical 5asa+-topical_ster	25	2.2	1.9	2.0	0.0	5.0	25	0.1	1.6	0.0	-4.0	3.0
immunomodulators (AZA+-MTX)	1	5.0	.	5.0	5.0	5.0	1	-5.0	.	-5.0	-5.0	-5.0
Biologicals with any of aboth combination	1	5.0	.	5.0	5.0	5.0	1	2.0	.	2.0	2.0	2.0
Disease activity (relapse) baseline yes no												
yes	6	3.3	2.0	4.0	1.0	5.0	6	0.3	2.9	1.5	-5.0	3.0
no	23	2.2	1.9	2.0	0.0	5.0	23	-0.2	1.5	0.0	-4.0	3.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 53 of 77

Treatment intervention

	HBI1						Dif HBI					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	9	5.9	2.9	7.0	2.0	10.0	9	-2.6	2.9	-3.0	-7.0	2.0
Age 35												
0	4	4.0	2.2	3.5	2.0	7.0	4	-1.8	3.5	-1.5	-6.0	2.0
1	5	7.4	2.7	8.0	3.0	10.0	5	-3.2	2.6	-3.0	-7.0	0.0
IBD duration												
0	2	5.0	2.8	5.0	3.0	7.0	2	1.0	1.4	1.0	0.0	2.0
1	7	6.1	3.1	7.0	2.0	10.0	7	-3.6	2.4	-3.0	-7.0	0.0
Gender												
male	3	7.7	3.2	9.0	4.0	10.0	3	-4.0	2.6	-3.0	-7.0	-2.0
female	6	5.0	2.6	5.0	2.0	8.0	6	-1.8	3.0	-1.5	-6.0	2.0
Intestinal surgery yes vs. no												
yes	6	6.0	3.4	6.0	2.0	10.0	6	-3.2	2.3	-3.0	-7.0	0.0
no	3	5.7	2.3	7.0	3.0	7.0	3	-1.3	4.2	0.0	-6.0	2.0
Smoking												
never	2	3.5	0.7	3.5	3.0	4.0	2	-0.5	3.5	-0.5	-3.0	2.0
former smoker	5	6.0	3.4	7.0	2.0	10.0	5	-4.0	2.7	-4.0	-7.0	0.0
currently	2	8.0	1.4	8.0	7.0	9.0	2	-1.0	1.4	-1.0	-2.0	0.0
Diagnosis type												
CD	9	5.9	2.9	7.0	2.0	10.0	9	-2.6	2.9	-3.0	-7.0	2.0
UC	0	.	.	.	.	.	0	.	.	.	.	.
Therapy five levels at baseline												
.	6	5.2	2.5	5.5	2.0	8.0	6	-1.8	3.0	-1.5	-6.0	2.0
5-ASA+-topical 5asa+-topical_ster	2	6.0	4.2	6.0	3.0	9.0	2	-2.5	0.7	-2.5	-3.0	-2.0
immunomodulators (AZA+-MTX)	1	10.0	.	10.0	10.0	10.0	1	-7.0	.	-7.0	-7.0	-7.0
Biologicals with any of aboth combination	0	.	.	.	.	.	0	.	.	.	.	.
Disease activity (relapse) baseline yes no												
yes	0	.	.	.	.	.	0	.	.	.	.	.
no	9	5.9	2.9	7.0	2.0	10.0	9	-2.6	2.9	-3.0	-7.0	2.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 54 of 77

Treatment control

	HBI1						Dif HBI					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	12	6.9	4.9	5.5	0.0	14.0	12	-0.7	1.5	0.0	-4.0	1.0
Age 35												
0	6	6.0	6.4	4.0	0.0	14.0	6	-1.0	1.7	0.0	-4.0	0.0
1	6	7.8	3.1	7.5	5.0	13.0	6	-0.3	1.4	0.0	-3.0	1.0
IBD duration												
.	0	.	.	.	.	.	0	.	.	.	.	.
0	3	6.3	2.5	6.0	4.0	9.0	3	0.0	0.0	0.0	0.0	0.0
1	9	7.1	5.6	5.0	0.0	14.0	9	-0.9	1.7	0.0	-4.0	1.0
Gender												
male	2	7.0	2.8	7.0	5.0	9.0	2	0.5	0.7	0.5	0.0	1.0
female	10	6.9	5.4	5.5	0.0	14.0	10	-0.9	1.5	0.0	-4.0	0.0
Intestinal surgery yes vs. no												
yes	2	6.5	9.2	6.5	0.0	13.0	2	0.0	0.0	0.0	0.0	0.0
no	10	7.0	4.5	5.5	0.0	14.0	10	-0.8	1.6	0.0	-4.0	1.0
Smoking												
never	9	6.1	5.2	5.0	0.0	14.0	9	-0.6	1.5	0.0	-4.0	1.0
former smoker	2	9.5	4.9	9.5	6.0	13.0	2	0.0	0.0	0.0	0.0	0.0
currently	1	9.0	.	9.0	9.0	9.0	1	-3.0	.	-3.0	-3.0	-3.0
Diagnosis type												
CD	12	6.9	4.9	5.5	0.0	14.0	12	-0.7	1.5	0.0	-4.0	1.0
UC	0	.	.	.	.	.	0	.	.	.	.	.
Therapy five levels at baseline												
.	4	2.5	3.0	2.0	0.0	6.0	4	-0.5	1.0	0.0	-2.0	0.0
5-ASA+-topical 5asa+-topical_ster	0	.	.	.	.	.	0	.	.	.	.	.
immunomodulators (AZA+-MTX)	6	8.3	4.4	7.0	4.0	14.0	6	-0.5	1.8	0.0	-4.0	1.0
Biologicals with any of aboth combination	2	11.5	3.5	11.5	9.0	14.0	2	-1.5	2.1	-1.5	-3.0	0.0
Disease activity (relapse) baseline yes no												
yes	1	9.0	.	9.0	9.0	9.0	1	0.0	.	0.0	0.0	0.0
no	11	6.7	5.1	5.0	0.0	14.0	11	-0.7	1.6	0.0	-4.0	1.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 55 of 77

# Treatment intervention

	FC1						Dif FC					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	36	203.0	312.6	50.5	2.0	1259	34	-43.9	263.6	3.0	-849	613.0
Age 35												
0	12	237.3	418.3	25.0	2.0	1259	12	-84.8	299.0	9.0	-849	176.0
1	24	185.9	253.1	61.5	5.0	1032	22	-21.6	246.8	-0.5	-725	613.0
IBD duration												
0	14	288.0	440.0	43.0	2.0	1259	14	-26.9	338.8	14.0	-849	613.0
1	22	149.0	187.4	55.0	5.0	756.0	20	-55.9	204.5	-2.5	-725	251.0
Gender												
male	11	221.4	311.7	43.0	5.0	1032	11	33.5	250.5	12.0	-293	613.0
female	25	195.0	319.0	54.0	2.0	1259	23	-81.0	267.1	-6.0	-849	251.0
Intestinal surgery yes vs. no												
yes	9	185.0	163.1	174.0	14.0	410.0	8	-61.6	157.2	-21.5	-293	160.0
no	27	209.0	351.0	43.0	2.0	1259	26	-38.5	291.0	3.0	-849	613.0
Smoking												
never	15	224.4	384.6	43.0	2.0	1259	14	0.4	247.3	3.0	-509	613.0
former smoker	15	210.5	290.4	56.0	5.0	945.0	15	-98.8	302.0	3.0	-849	245.0
currently	6	131.0	160.2	48.5	17.0	410.0	5	-3.6	187.9	5.0	-293	176.0
Diagnosis type												
CD	10	153.3	169.1	48.5	2.0	410.0	10	-46.5	142.4	6.5	-293	160.0
UC	26	222.2	353.7	51.5	5.0	1259	24	-42.9	303.0	-0.5	-849	613.0
Therapy five levels at baseline												
.	8	74.3	89.0	37.5	2.0	250.0	7	30.3	58.5	12.0	-15.0	160.0
5-ASA+-topical 5asa+-topical_ster	22	201.2	316.6	57.0	5.0	1259	21	-68.3	246.3	-6.0	-849	251.0
immunomodulators (AZA+-MTX)	3	162.0	215.4	54.0	22.0	410.0	3	-56.7	234.5	-53.0	-293	176.0
Biologicals with any of aboth combination	3	600.7	526.5	756.0	14.0	1032	3	-34.0	670.1	10.0	-725	613.0
Disease activity (relapse) baseline yes no												
yes	5	616.6	574.7	756.0	14.0	1259	5	-87.0	537.1	10.0	-725	613.0
no	31	136.3	191.9	47.0	2.0	945.0	29	-36.5	200.8	3.0	-849	251.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 56 of 77

# Treatment control

	FC1						Dif FC					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	37	217.9	404.0	39.0	2.0	1600	34	-30.1	231.8	3.0	-1126	340.0
Age 35												
0	12	246.2	471.4	40.5	9.0	1482	11	-20.1	147.7	2.0	-309	243.0
1	25	204.4	377.3	31.0	2.0	1600	23	-34.9	265.7	4.0	-1126	340.0
IBD duration												
.	1	5.0	.	5.0	5.0	5.0	1	2.0	.	2.0	2.0	2.0
0	16	250.9	446.3	40.5	2.0	1600	15	-67.8	338.0	6.0	-1126	340.0
1	20	202.2	385.3	35.0	4.0	1482	18	-0.5	89.1	3.0	-254	243.0
Gender												
male	7	679.4	687.1	684.0	2.0	1600	5	-274	489.3	-2.0	-1126	11.0
female	30	110.2	203.7	30.5	3.0	952.0	29	11.9	129.1	4.0	-309	340.0
Intestinal surgery yes vs. no												
yes	1	8.0	.	8.0	8.0	8.0	1	40.0	.	40.0	40.0	40.0
no	36	223.8	408.1	39.5	2.0	1600	33	-32.2	235.0	2.0	-1126	340.0
Smoking												
never	26	291.5	462.0	58.5	5.0	1600	23	-36.3	278.9	2.0	-1126	340.0
former smoker	11	44.0	80.9	8.0	2.0	269.0	11	-17.1	76.4	6.0	-242	40.0
currently	0	.	.	.	.	.	0	.	.	.	.	.
Diagnosis type												
CD	10	355.4	548.7	39.5	8.0	1600	9	-124	401.1	4.0	-1126	243.0
UC	27	167.0	334.4	39.0	2.0	1482	25	3.5	125.6	2.0	-254	340.0
Therapy five levels at baseline												
.	5	20.6	18.6	10.0	5.0	49.0	5	51.0	107.4	2.0	-2.0	243.0
5-ASA+-topical 5asa+-topical_ster	25	179.8	344.7	40.0	2.0	1482	23	3.8	131.2	4.0	-254	340.0
immunomodulators (AZA+-MTX)	6	574.0	631.2	435.0	8.0	1600	5	-278	494.5	0.0	-1126	40.0
Biologicals with any of aboth combination	1	22.0	.	22.0	22.0	22.0	1	24.0	.	24.0	24.0	24.0
Disease activity (relapse) baseline yes no												
yes	5	802.0	704.9	621.0	68.0	1600	5	-204	556.7	-2.0	-1126	340.0
no	32	126.7	248.6	26.0	2.0	952.0	29	-0.1	112.6	4.0	-309	340.0



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 57 of 77

Treatment intervention

	CRP1						Dif CRP					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	37	4.0	6.1	2.0	2.0	35.0	37	-0.5	7.8	0.0	-31.0	26.0
Age 35												
0	13	2.8	2.0	2.0	2.0	9.0	13	2.9	8.3	0.0	-7.0	26.0
1	24	4.6	7.5	2.0	2.0	35.0	24	-2.4	7.0	0.0	-31.0	0.0
IBD duration												
0	15	3.5	4.3	2.0	2.0	18.0	15	1.3	9.0	0.0	-16.0	26.0
1	22	4.3	7.2	2.0	2.0	35.0	22	-1.7	6.8	0.0	-31.0	3.0
Gender												
male	12	5.9	9.6	2.0	2.0	35.0	12	-2.2	10.2	0.0	-31.0	14.0
female	25	3.0	3.4	2.0	2.0	18.0	25	0.3	6.4	0.0	-16.0	26.0
Intestinal surgery yes vs. no												
yes	10	6.3	10.4	2.0	2.0	35.0	10	-3.1	9.9	0.0	-31.0	3.0
no	27	3.1	3.4	2.0	2.0	18.0	27	0.4	6.8	0.0	-16.0	26.0
Smoking												
never	15	2.6	1.6	2.0	2.0	8.0	15	2.4	7.7	0.0	-6.0	26.0
former smoker	16	4.5	8.3	2.0	2.0	35.0	16	-2.2	7.9	0.0	-31.0	3.0
currently	6	6.0	6.7	2.0	2.0	18.0	6	-3.3	6.4	0.0	-16.0	0.0
Diagnosis type												
CD	11	7.8	10.4	2.0	2.0	35.0	11	-5.0	10.1	0.0	-31.0	3.0
UC	26	2.3	1.2	2.0	2.0	8.0	26	1.4	5.9	0.0	-6.0	26.0
Therapy five levels at baseline												
.	8	4.9	5.8	2.0	2.0	18.0	8	-2.5	6.1	0.0	-16.0	3.0
5-ASA+-topical 5asa+-topical_ster	22	2.4	1.7	2.0	2.0	10.0	22	1.7	6.3	0.0	-4.0	26.0
immunomodulators (AZA+-MTX)	3	13.0	19.1	2.0	2.0	35.0	3	-10.3	17.9	0.0	-31.0	0.0
Biologicals with any of aboth combination	4	4.0	2.8	3.0	2.0	8.0	4	-1.3	3.2	0.0	-6.0	1.0
Disease activity (relapse) baseline yes no												
yes	6	3.5	2.3	2.5	2.0	8.0	6	3.5	11.3	0.0	-6.0	26.0
no	31	4.1	6.6	2.0	2.0	35.0	31	-1.3	6.9	0.0	-31.0	14.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 58 of 77

Treatment control

	CRP1						Dif CRP					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	41	4.3	8.6	2.0	2.0	52.0	41	-1.4	4.4	0.0	-18.0	0.0
Age 35												
0	13	4.1	5.2	2.0	2.0	18.0	13	-2.0	5.0	0.0	-16.0	0.0
1	28	4.4	9.9	2.0	2.0	52.0	28	-1.2	4.2	0.0	-18.0	0.0
IBD duration												
.	1	2.0	.	2.0	2.0	2.0	1	0.0	.	0.0	0.0	0.0
0	17	3.7	5.0	2.0	2.0	20.0	17	-1.6	4.9	0.0	-18.0	0.0
1	23	4.9	10.8	2.0	2.0	52.0	23	-1.4	4.3	0.0	-16.0	0.0
Gender												
male	7	9.1	18.9	2.0	2.0	52.0	7	-2.0	5.3	0.0	-14.0	0.0
female	34	3.3	4.4	2.0	2.0	20.0	34	-1.3	4.3	0.0	-18.0	0.0
Intestinal surgery yes vs. no												
yes	2	2.0	0.0	2.0	2.0	2.0	2	0.0	0.0	0.0	0.0	0.0
no	39	4.4	8.8	2.0	2.0	52.0	39	-1.5	4.6	0.0	-18.0	0.0
Smoking												
never	29	5.3	10.2	2.0	2.0	52.0	29	-2.0	5.2	0.0	-18.0	0.0
former smoker	11	2.0	0.0	2.0	2.0	2.0	11	0.0	0.0	0.0	0.0	0.0
currently	1	2.0	.	2.0	2.0	2.0	1	0.0	.	0.0	0.0	0.0
Diagnosis type												
CD	12	7.1	14.5	2.0	2.0	52.0	12	-2.0	4.7	0.0	-14.0	0.0
UC	29	3.2	4.4	2.0	2.0	20.0	29	-1.2	4.4	0.0	-18.0	0.0
Therapy five levels at baseline												
.	6	2.0	0.0	2.0	2.0	2.0	6	0.0	0.0	0.0	0.0	0.0
5-ASA+-topical 5asa+-topical_ster	25	3.4	4.7	2.0	2.0	20.0	25	-1.4	4.7	0.0	-18.0	0.0
immunomodulators (AZA+-MTX)	7	10.7	18.7	2.0	2.0	52.0	7	-3.4	6.0	0.0	-14.0	0.0
Biologicals with any of aboth combination	3	2.0	0.0	2.0	2.0	2.0	3	0.0	0.0	0.0	0.0	0.0
Disease activity (relapse) baseline yes no												
yes	7	4.3	6.0	2.0	2.0	18.0	7	-2.3	6.0	0.0	-16.0	0.0
no	34	4.3	9.1	2.0	2.0	52.0	34	-1.3	4.1	0.0	-18.0	0.0

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 59 of 77

# Treatment intervention


	FODMAPS1						Dif FODMAPS					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	37	27.4	15.5	23.7	8.8	80.8	33	-19.6	16.7	-19.0	-80.6	1.4
Age 35												
0	13	29.6	14.0	24.3	8.8	50.0	11	-19.2	13.3	-21.7	-49.0	0.0
1	24	26.2	16.5	20.7	9.0	80.8	22	-19.7	18.4	-17.7	-80.6	1.4
IBD duration												
0	15	28.8	14.2	24.3	9.0	50.0	12	-15.1	8.6	-16.1	-27.0	0.0
1	22	26.4	16.6	21.6	8.8	80.8	21	-22.1	19.6	-19.4	-80.6	1.4
Gender												
male	12	23.8	12.8	20.3	8.8	49.0	12	-13.3	12.1	-9.4	-43.0	0.0
female	25	29.1	16.7	23.7	10.0	80.8	21	-23.1	18.1	-19.8	-80.6	1.4
Intestinal surgery yes vs. no												
yes	10	28.1	15.1	25.2	8.8	50.6	9	-25.3	18.0	-24.5	-49.0	-2.0
no	27	27.1	16.0	22.0	9.0	80.8	24	-17.4	16.0	-17.7	-80.6	1.4
Smoking												
never	15	30.0	19.4	24.0	8.8	80.8	12	-18.8	21.2	-13.7	-80.6	0.0
former smoker	16	24.3	11.0	22.8	9.0	50.6	16	-19.4	13.3	-18.8	-48.7	0.0
currently	6	29.2	16.2	22.2	12.5	50.0	5	-21.9	18.0	-20.0	-49.0	1.4
Diagnosis type												
CD	11	30.5	15.5	26.5	8.8	50.6	10	-27.1	15.1	-23.7	-49.0	-7.0
UC	26	26.1	15.7	20.9	9.0	80.8	23	-16.3	16.6	-15.2	-80.6	1.4
Therapy five levels at baseline												
.	8	28.4	14.5	24.0	8.8	50.6	6	-24.4	13.1	-22.3	-48.7	-8.8
5-ASA+-topical 5asa+-topical_ster	22	25.9	17.3	19.7	9.0	80.8	20	-16.4	17.5	-12.9	-80.6	1.4
immunomodulators (AZA+-MTX)	3	38.8	12.9	43.0	24.3	49.1	3	-38.2	13.8	-43.0	-49.0	-22.6
Biologicals with any of aboth combination	4	25.2	5.6	26.0	19.0	30.0	4	-14.0	10.1	-14.5	-25.0	-2.0
Disease activity (relapse) baseline yes no												
yes	6	29.2	11.1	27.2	19.0	50.0	5	-15.7	9.6	-19.0	-25.0	-2.0
no	31	27.1	16.4	21.3	8.8	80.8	28	-20.2	17.7	-19.0	-80.6	1.4

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 60 of 77


Treatment control

	FODMAPS1						Dif FODMAPS					
	N	Mean	Std	Median	Min	Max	N	Mean	Std	Median	Min	Max
All	41	27.8	12.9	25.9	3.9	57.7	40	-1.4	11.6	0.0	-34.9	29.1
Age 35												
0	13	25.8	14.4	23.1	3.9	57.7	13	-0.5	12.8	0.0	-34.9	17.3
1	28	28.8	12.3	27.3	5.0	51.4	27	-1.9	11.2	0.0	-27.3	29.1
IBD duration												
.	1	17.0	.	17.0	17.0	17.0	1	-3.0	.	-3.0	-3.0	-3.0
0	17	27.4	12.1	27.0	5.0	57.7	16	-2.3	11.1	0.0	-27.3	19.1
1	23	28.6	13.8	25.9	3.9	51.4	23	-0.7	12.4	0.0	-34.9	29.1
Gender												
male	7	28.6	12.1	27.6	13.4	46.0	7	-3.8	6.8	0.0	-14.0	1.0
female	34	27.7	13.2	25.5	3.9	57.7	33	-0.9	12.4	0.0	-34.9	29.1
Intestinal surgery yes vs. no												
yes	2	35.5	16.2	35.5	24.0	47.0	2	-1.0	1.4	-1.0	-2.0	0.0
no	39	27.4	12.8	25.9	3.9	57.7	38	-1.4	11.9	0.0	-34.9	29.1
Smoking												
never	29	27.4	13.8	25.1	3.9	57.7	29	0.3	10.7	0.0	-34.9	29.1
former smoker	11	27.5	10.1	27.0	12.4	46.0	10	-4.7	12.9	-1.0	-27.3	19.1
currently	1	45.0	.	45.0	45.0	45.0	1	-20.0	.	-20.0	-20.0	-20.0
Diagnosis type												
CD	12	36.8	10.7	36.8	23.1	57.7	12	-3.9	13.3	-0.1	-34.9	14.7
UC	29	24.1	12.0	22.7	3.9	51.4	28	-0.3	10.9	0.0	-27.3	29.1
Therapy five levels at baseline												
.	6	30.3	10.6	29.5	17.0	47.0	6	-0.5	1.2	0.0	-3.0	0.0
5-ASA+-topical 5asa+-topical_ster	25	24.9	12.2	22.9	3.9	51.4	24	-1.1	9.9	0.0	-27.3	19.1
immunomodulators (AZA+-MTX)	7	33.9	15.9	36.7	8.8	57.7	7	5.3	13.9	0.0	-13.4	29.1
Biologicals with any of aboth combination	3	33.3	13.8	36.9	18.1	45.0	3	-21.4	12.9	-20.0	-34.9	-9.2
Disease activity (relapse) baseline yes no												
yes	7	20.4	10.6	16.0	8.8	36.7	7	0.9	13.6	0.0	-13.4	29.1
no	34	29.4	12.9	26.7	3.9	57.7	33	-1.9	11.3	0.0	-34.9	19.1

Figure 10: Alternative plots for IBS\_SSS including regression lines




Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 62 of 77




TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_SSS	Intercept	-29.31	48.26	0.5475	37	8.84
intervention	D_SSS	SSS1	-0.36	0.20	0.0739	37	.
control	D_SSS	Intercept	-3.98	39.35	0.9199	41	7.30
control	D_SSS	SSS1	-0.26	0.15	0.0876	41	.

Figure 11: Alternative plots for IBS\_QOL including regression lines





Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 64 of 77




TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_QOL	Intercept	11.63	6.78	0.0955	36	1.86
intervention	D_QOL	QOL1	-0.08	0.10	0.4273	36	.
control	D_QOL	Intercept	3.16	6.49	0.6287	41	0.38
control	D_QOL	QOL1	-0.03	0.09	0.7020	41	.



Figure 12: Alternative plots for IBDQ including regression lines




Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 66 of 77




TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_IBDQ	Intercept	40.40	7.46	<.0001	33	37.26
intervention	D_IBDQ	IBDQ1	-0.65	0.15	0.0002	33	.
control	D_IBDQ	Intercept	0.39	6.88	0.9554	38	0.02
control	D_IBDQ	IBDQ1	0.01	0.14	0.9372	38	.

Figure 13: Alternative plots for SCCAI including regression lines




Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 68 of 77




TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_SCCAI	Intercept	1.13	0.81	0.1774	24	25.55
intervention	D_SCCAI	SCCAI1	-0.71	0.26	0.0117	24	.
control	D_SCCAI	Intercept	0.44	0.55	0.4360	29	4.73
control	D_SCCAI	SCCAI1	-0.21	0.18	0.2572	29	.

Figure 14: Alternative plots for HBI including regression lines





Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 70 of 77



TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_HBI	Intercept	1.00	1.95	0.6243	9	36.74
intervention	D_HBI	HBI1	-0.60	0.30	0.0836	9	.
control	D_HBI	Intercept	0.13	0.75	0.8670	12	14.28
control	D_HBI	HBI1	-0.11	0.09	0.2258	12	.

Figure 15: Alternative plots for FC including regression lines








TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_FC	Intercept	33.40	48.24	0.4937	34	21.67
intervention	D_FC	FC1	-0.38	0.13	0.0055	34	.
control	D_FC	Intercept	48.09	31.94	0.1420	34	49.40
control	D_FC	FC1	-0.41	0.07	<.0001	34	.




Figure 16: Alternative plots for FC including regression lines






TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_CRP	Intercept	3.39	0.99	0.0016	37	59.62
intervention	D_CRP	CRP1	-0.98	0.14	<.0001	37	.
control	D_CRP	Intercept	0.37	0.46	0.4286	41	66.45
control	D_CRP	CRP1	-0.42	0.05	<.0001	41	.

Figure 17: Alternative plots for FC including regression lines



Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 76 of 77



TREATMENT	Dependent	Parameter	Estimate	StdErr	P value	NObsUsed	R_square_pct
intervention	D_FODMAPS	Intercept	3.08	3.56	0.3927	33	63.56
intervention	D_FODMAPS	FODMAPS1	-0.88	0.12	<.0001	33	.
control	D_FODMAPS	Intercept	8.31	4.08	0.0488	40	15.35
control	D_FODMAPS	FODMAPS1	-0.35	0.13	0.0124	40	.

Larix A/S	Study: IBD-IBS CTR	Date: 07OCT2016
Confidential	Version: Final 1.0	Page 77 of 77

**Table16: FODMAPS at baseline: analysis of COVARIANCE**

Effect	contrast	Base_FODMAPS	Lower	Upper	p_value
AGE35	Below 35 years vs. above	-3.1656	-11.2175	4.8862	0.4350
Surgery	No vs. Yes	1.7695	-9.4398	12.9789	0.7535
Smoking	Current vs. never	-1.1345	-13.4549	11.1860	0.8546
Smoking	Former vs. never	-4.1723	-12.0413	3.6967	0.2934
IBD durati	Below 5 years vs. above	2.8497	-4.3694	10.0688	0.4332
BMI	Per kg/m2	0.02802	-0.6197	0.6758	0.9314
Gender	Females versus males	2.7655	-5.3947	10.9256	0.5007
Diagnosis	CD vs. UC	8.1773	-4.4782	20.8327	0.2013
Treat BL	5ASA vs none	-0.4267	-12.9221	12.0688	0.9458
Treat BL	Biol, vs none	3.5257	-12.1938	19.2452	0.6555
Treat BL	Immuno vs none	5.1895	-7.9309	18.3099	0.4323
Remission	No vs. Yes	4.7126	-7.1124	16.5377	0.4288

The baseline FODMAPS is considered a continuous dependent variable and is treated using a linear normal analysis of covariance (ANCOVA) with covariates: Treatment at baseline, Gender, Age35, Smoking status, UC/CD, Surgery before baseline, years since IBD diagnosis and BMI. Note that BMI is used as regression variable.

**Table17: Change from baseline in FODMAPS: analysis of COVARIANCE**

Effect	contrast	DIFF_FODMAPS	Lower	Upper	p_value
FODMAPS1	Per baseline FODMAPS point	-0.6627	-0.8791	-0.4462	<.0001
AGE35	Below 35 years vs. above	-0.6188	-7.5176	6.2800	0.8581
Surgery	No vs. Yes	0.004147	-10.4510	10.4593	0.9994
Smoking	Current vs. never	-5.5367	-16.8048	5.7313	0.3292
Smoking	Former vs. never	-4.6575	-11.5051	2.1900	0.1785
IBD durati	Below 5 years vs. above	-0.00587	-6.0988	6.0870	0.9985
BMI	Per kg/m2	0.2383	-0.2908	0.7673	0.3708
Gender	Females versus males	-4.3242	-11.2548	2.6064	0.2165
Diagnosis	CD vs. UC	-6.7492	-18.5412	5.0427	0.2564
<b>TREATMENT</b>	<b>Control vs. Intervention</b>	<b>18.1502</b>	<b>11.5728</b>	<b>24.7276</b>	<b>&lt;.0001</b>
Treat BL	5ASA vs none	-5.7809	-17.3328	5.7710	0.3204
Treat BL	Biol, vs none	-5.2353	-18.6954	8.2247	0.4392
Treat BL	Immuno vs none	4.3215	-7.1506	15.7936	0.4536
Remission	No vs. Yes	3.1818	-7.2668	13.6305	0.5443

The change in FODMAPS is analyzed using the same model, EXCEPT for the inclusion of the baseline FODMAPS value as regression variable and the Treatment effect.